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ABSTRACT
This study examined the effect o f sedentary living versus low intensity exercise
training on insulin sensitivity and vascular responsiveness and on the eNOS-Hsp90
interaction in rat aorta.

It was hypothesized that sedentary living would result in

decreased insulin sensitivity and vascular responsiveness coupled with a decreased
eNOS-Hsp90 interaction and that long term low intensity exercise would prevent these
changes.

Thirty male Sprague-Dawley rats were randomly divided into exercise (E),

sedentary (S), and baseline (B) groups. E rats exercised on a treadmill up to a speed of
15 m/min for 30 min, 4 d/wk, for 14-17 wks.

Average body weights were not

significantly different between the E and S groups throughout the entire study. HOMAIR values were greater in both E and S groups at week 14 compared to week 0 (P<0.05).
Insulin caused dose-dependent vasorelaxation responses in isolated aortic rings which
were lower in the E group compared to the S group at several insulin concentrations
(P<0.05). The B group had a greater rate o f change in insulin-mediated vasorelaxation
compared to both E and S groups (P<0.05).

The level o f eNOS and Hsp90 protein

interaction was not significantly different between the E, S, and B groups. In summary,
long term sedentary living resulted in decreased insulin sensitivity, which low intensity
exercise training did not prevent. Contrary to the hypothesis, long term low intensity
exercise resulted in decreased insulin-mediated vasorelaxation of the aorta with no
change in the eNOS-Hsp90 interaction.

Keywords: exercise, sedentary, insulin, acetylcholine, vasorelaxation, vasodilation,
endothelial nitric oxide synthase, heat shock protein 90, co-immunoprecipitation, aorta
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CHAPTER 1
1.1 Introduction
Cardiovascular disease (CVD) is a major cause of increased morbidity and
mortality in many regions o f the world, with prevalence of diseases such as hypertension
as high as 34% (160). CVD is an umbrella term which encompasses both heart disease,
like pathological hypertrophy and heart failure, and disease of the vascular system, like
atherosclerosis. These diseases, which often occur simultaneously in a single individual,
pose a significant threat to longevity and quality of life (160). CVDs are very complex
and involve many factors that both accelerate or decelerate the accumulation of
abnormalities. Factors involved are usually divided into non-modifiable factors, such as
one’s genetic information, and modifiable factors, such as lifestyle. O f importance in the
prevention and treatment o f CVDs are the modifiable factors which are affected by and
work in conjunction with an individual’s genetically-inherited predispositions to increase
or decrease the rate o f development of CVD. Just as the various CVDs tend to cluster in
a single individual, so too do the risk factors (42; 119; 160). These risk factors, which
also serve as criteria to indicate the presence of disease, include greater visceral
adiposity, blood hyperlipidemia and hyperglycemia, and insulin resistance (42; 119; 160).
The clustering o f these CVD risk factors and others has indeed been recognized and
labelled by several healthcare organizations as the metabolic syndrome (42; 119). This
state o f increased disease risk is influenced by many factors, such as nutritional intake,
exposure to hazardous compounds, and physical activity (42; 119). O f particular interest
in this study, is the effect of regular physical activity or the lack thereof.

1.2 The metabolic syndrome and its cardiovascular complications
A. Defining the metabolic syndrome
The metabolic syndrome has been defined by several health organizations
including the World Health Organization (WHO) (4) and the National Cholesterol
Education Program’s Adult Training Panel III (NCEP:ATPIII) (1) and the International
Diabetes Federation (3). Each definition varies slightly from the others. All definitions,
however, centre on several common factors that, when present, increase the likelihood of
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developing CVD (79).

Risk factors include insulin resistance, obesity, and blood

hyperlipidemia (42; 119). For instance, the WHO has defined metabolic syndrome as the
presence o f impaired glucose regulation or diabetes, as determined by fasting blood
glucose concentrations and glucose tolerance tests; insulin resistance as determined by
the

euglycemic-hyperinsulinemic

clamp

technique;

hypertension;

blood

hypertriglyceridemia and/or decreased high density lipoprotein (HDL) cholesterol
concentration; central obesity as determined by waist-to-hip ratios; and microalbuminuria
as determined by urinary albumin excretion or the albumin to creatinine ratio in urine (4).
The NCEP:ATPIII, on the other hand, has defined the metabolic syndrome as the
presence of abdominal obesity, as determined by waist circumference; blood
hypertriglyceridemia and decreased blood HDL cholesterol concentration; hypertension;
and fasting blood hyperglycemia (1). The metabolic syndrome is certainly not an all-ornone condition.

It is a gradually-occurring deviation from what may be termed

“healthy”. The deviations, over the course o f years, accumulate and lead to further
dysfunction to eventually transform from a mere syndrome into a full-fledged clinicallyrecognized CVD (42; 79; 119). CVD refers to several diseases which, according to the
WHO’s International Classification o f Diseases, includes ischemic heart disease,
cerebrovascular disease, essential hypertension, and atherosclerosis, among many others
(160). Given the nature o f different CVDs, it is clear that the metabolic syndrome can
lead to a diverse set o f complications.

B. Insulin resistance
It is typically acknowledged that one o f the central aspects o f the metabolic
syndrome is insulin resistance (4; 42; 119).

Insulin is a multi-unit peptide hormone

released from the P cells o f the Islets o f Langerhans of the pancreas. It acts on several
tissues in the body, including skeletal muscle, adipose tissue and the liver, to promote the
storage o f carbohydrate, lipids, and protein (162; 205). Its traditionally-recognized role
in the body, however, is the promotion o f glucose removal (also known as glucose
disposal or glucose clearance) from the blood. The ability to remove glucose, following
glucose and/or insulin infusions, is examined in glucose tolerance tests (59) or
euglycemic-hyperinsulinemic clamp protocols (49). The degree o f insulin resistance can
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be inferred from such procedures. In an insulin resistant state, the body is less effective
at removing glucose from the blood. Typically in the early stages of insulin resistance,
the body compensates for a diminished insulin-mediated glucose removal by increasing
the production o f insulin from the pancreas (147; 172).

In this way, blood glucose

concentrations can be maintained at a “normal” level.
However, insulin resistance is more complicated than a simple decrease in insulin
receptor activation, as there is evidence that there is a “selective” downregulation of
some, but not all, o f the cell signalling pathways activated by the insulin receptor (33; 34;
43; 86; 100; 217).

This means that although the body can successfully maintain

euglycemia via an increase o f insulin concentration, the greater insulin concentration may
also upregulate other signalling pathways not directly involved with glucose removal.
These alternate signalling pathways, such as the mitogen activated protein kinase
(MAPK) and the Janus kinase (JAK)/signal transducer and activator of transcription
(STAT) pathways, can themselves lead to further dysfunction (136) and to further insulin
resistance (98; 123), thus producing a vicious cycle.

Eventually, pancreatic (3 cell

function declines and insulin resistance cannot be compensated for by hyperinsulinemia
(27). Overt hyperglycemia and type 2 diabetes (T2DM) ensue. Chronic hyperglycemia
itself is a major stressor in most body tissues. It leads to chemical modifications, such as
the glycation and oxidation of proteins (24), and this in turn leads to a variety of
dysfunctions (189; 221). Glycated macromolecules can also activate particular signalling
pathways leading to deleterious effects such as oxidative stress and excessive
inflammation (24; 199). The accumulation of the numerous insults over time promotes
the development o f CVD and it is clear then that preventing insulin resistance would be
an important step to preventing disease.

C. Contribution o f blood flow to insulin-mediated glucose disposal
When insulin binds to its receptor on the cell membrane, it upregulates multiple
intertwining signalling cascades which can cause a multitude o f cellular responses. In its
traditional role o f reducing blood glucose concentration, the insulin receptor (IR)
activates the

signalling cascade to

increase the translocation o f the glucose
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transmembrane carrier protein, Glucose Transporter 4 (GLUT4), to the cell membrane.
The activated GLUT4 then facilitates the diffusion of glucose into the cell (162).
The skeletal muscle mass is one of the largest insulin target organs in the body
and thus is a major sink for glucose removal. Therefore, the ability o f skeletal muscle to
uptake glucose from the blood is likely a major determinant o f systemic insulin
resistance.

Furthermore, the ability o f muscle to uptake glucose may be partially

influenced by its blood supply (14; 16; 124; 139), since it is the blood that carries glucose
to every organ. In other words, an increased blood flow to muscle would increase its
supply o f glucose, and insulin, and this may increase the amount of glucose able to be
removed (124).

As it turns out, insulin itself can increase blood flow by causing a

vasodilation o f arteries ( 6 ; 136), and so this mechanism may be a part o f the insulinmediated glucose removal (16; 124). It can be conjectured then, that impaired insulinmediated vasodilation can lead to decreased supply o f glucose, especially to muscle, and
this could result in impaired glucose removal. Indeed, mice unable to vasodilate through
nitric oxide (NO), displayed impaired insulin sensitivity during a euglycemichyperinsulinemic clamp technique (173). This finding suggests that an impaired ability
to increase blood flow also causes insulin resistance. The evidence for the contribution of
impaired insulin-mediated vasodilation to insulin resistance is not unanimous, however.
In addition to the study by Shankar and colleagues (173), there is also evidence that
merely increasing blood flow through insulin-independent mechanisms improves insulinmediated glucose removal (124), but not all studies demonstrate such an effect (139).

1.3 Vascular function and regulation
A. Control o f blood flow
The vascular system’s major roles are the delivery of oxygenated blood and
nutrients to all o f the tissues of the body, and also the removal o f metabolic waste
products from those tissues. The heart is the central pump that continuously generates
the pressure to circulate blood through the vascular system.
system is not itself passive.

However, the vascular

It plays a major role in blood flow distribution through

increases (vasodilation) and decreases (vasoconstriction) o f vessel lumen diameter. Both
vasodilation and vasoconstriction are essential to blood flow control, and the body keeps
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an intricately regulated balance of each. Importantly, vasodilation and vasoconstriction
are relative terms. They don’t define a particular range o f vessel diameters, but define a
change in diameter from a prior state. Hence, vasodilation is simply a relative increase in
vessel diameter from a previously-held diameter, and does not mean a state characterized
by large vessel diameters.

Before examining factors involved in the regulation of

vasodilation and vasoconstriction, it is important to outline specific terms used here and
in the literature. Vasodilation and vasoconstriction refer most precisely to changes in
vessel diameter, as described above.

The analogous terms vasorelaxation and

vasocontraction refer to changes in vessel wall tension.

In the intact organism,

vasodilation occurs through a decrease in vessel wall tension, and therefore occurs
concurrently with vasorelaxation.
vasocontraction.

The same is true for vasoconstriction and

However, in some experimental conditions, particularly in in vitro

examinations o f isolated vessels, vasorelaxation or vasocontraction are observed without
changes in diameter (176).
Vessel tension is determined by many mechanisms which converge on several
major factors, including the passive elastic components of the vascular wall, and the
vascular smooth muscle (VSM) contraction level.

The elastic properties o f vascular

walls are determined largely by the relative amounts of extracellular matrix components,
such as collagen and elastin. These make up the connective tissue that maintains the
shape o f the vessel (112; 211). This aspect, however, will not be discussed here, and
instead this discussion will focus on the VSM contraction level which is under acute
control. VSM cells (VSMC) wrap circumferentially around blood vessels in a roughly
transverse orientation relative to the direction of blood flow in the lumen of the vessel
(203). Upon contraction, the blood vessel lumen is made smaller.
VSM contraction, like any other physiological phenomenon, is controlled by a
wide variety o f factors.

These factors may be conceptually divided into two types:

physical factors such as stretch and compression, and chemical factors which bind to
receptors to alter cell signalling pathways and intracellular ion concentrations.

The

chemical regulation o f VSM contraction can be further divided into neural and bloodborne factors. The sympathetic nervous system (SNS) directly innervates VSM in all
areas o f the body to typically cause a vasocontraction response. O f course, the contractile
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response really depends on the target cell’s cellular response to neurotransmitters.
Blood-borne factors, however, may act indirectly to affect VSM contraction level. They
may bind to receptors on the inner lining o f blood vessels, the endothelium, which in turn
integrates, modifies, and transduces signals to the VSM.
The importance o f endothelial cells (EC) in controlling VSM contraction is
paramount, especially considering the large variety o f blood-borne factors, such as
hormones and cytokines. Both relaxing and contracting factors are produced in ECs in
response to various agents. As an example to help illustrate the role o f ECs in regulating
VSM contraction, the effect o f stimulation with acetylcholine (ACh) will be examined.
Acetylcholine normally produces an endothelium-dependent vasodilation response
through the M 3-muscarinic receptor (21; 78; 97). An alteration o f the amount of ACh
alters the cellular response o f ECs, and through signal transduction, alters the response of
VSM.

However, the EC M 3 signal transduction pathways may themselves be altered

independent o f changes in extracellular ACh concentrations. For instance, for a given
concentration o f ACh, there could be a decreased production o f EC-derived NO, and thus
a decreased VSM relaxation response. The effective relaying o f extracellular signals in
ECs is therefore critically important in determining VSM contraction level. Indeed, one
o f the most common etiological factors present in vascular diseases is endothelial
dysfunction (25; 218).

B. Endothelial dysfunction in CVD
Endothelial dysfunction can be defined as the disruption o f the balance between
vasodilatory and vasoconstrictive effects, in which an EC stimulant, traditionally ACh,
elicits a diminished vasodilation response compared to normally-functioning ECs.
Consequently, because o f disrupted balance, in a state of endothelial dysfunction there is
also increased vasoconstricting capability (36; 184; 206), which is o f great importance in
controlling both blood flow and blood pressure. This definition takes a limited view on
endothelial dysfunction, as the endothelium also participates in controlling other factors
involved in vascular health, including leukocyte adhesion and infiltration, VSM cell
proliferation and migration, and angiogenesis. For the purposes of this study, the focus
will be on the regulation of VSM tension.

Indeed, decreased vasodilatory ability, or
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endothelial dysfunction, often occurs concomitantly with other deleterious processes such
as enhanced leukocyte adhesion and VSM cell proliferation (29; 30; 166). This is due to
the fact that the various processes under EC control are regulated by a handful of
common factors, such as NO.

In other words, the signal transduction pathways

determining the extent o f the vasodilation response also determine the extent of leukocyte
adhesion, for instance, and thus a perturbation in one event likely coexists with a
perturbation in another.

This principle allows researchers to examine endothelial

dysfunction from the point o f view o f vasodilation, with the ability then to provide
implications for the other aspects o f endothelial dysfunction and vascular disease.

C. Vascular action o f insulin
Endothelium-dependent vasodilation occurs in response to a number o f
traditionally-used stimuli such as ACh, bradykinin, and shear stress.

However, in

addition to its metabolic effects, insulin has also been shown to be vasoactive, resulting in
changes in blood flow, as mentioned above.

Insulin can cause increases in vessel

diameter (197), increases in blood flow (32; 38; 46; 120; 177; 200), and decreased
vascular resistance (157; 169; 177) and these responses occur at physiological
concentrations of insulin. It has been demonstrated that this effect is mostly due to the
production o f NO (177; 195; 196). Insulin-mediated vasodilation is regulated in a spatial
and temporal manner.

Acute hyperinsulinemia initially promotes capillary bed

recruitment via vasodilation o f terminal arterioles (40; 157; 196) and only later promotes
vasodilation o f larger resistance arteries to increase total blood flow (198). Furthermore,
increased blood volume in particular skeletal muscle capillary beds occurs well before
increases in total limb blood flow, which can peak by approximately 2 hours (13; 200).
These effects have been observed in studies using exogenous insulin infusions (32; 38;
46; 120) and also in studies using a glucose-mediated endogenous insulin release (169;
197; 200).
The link between insulin-mediated glucose uptake and blood flow is not entirely
clear. Although increased skeletal muscle blood flow increases delivery o f both insulin
and glucose, and the insulin-mediated increase in blood flow may account for up to 3040% of the insulin-mediated glucose clearance (13; 195), vasodilation ability may not
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require blood glucose removal, and may occur independently of glucose uptake (154;
200). However, evidence o f this in vivo glucose-independent function is equivocal as
others have shown a necessity for concomitant glucose uptake (38; 187). In vitro, insulin
has a clear capacity to cause vasorelaxation responses in isolated vessels (60; 61; 103;
104; 114; 118; 167; 179; 180; 213; 215; 222) or in entire vascular beds (150). It also
inhibits vasoconstriction responses in isolated vessels (47; 130; 193), and even directly
decreases VSM cell contraction in cell culture models (114; 163). Evidence for insulin’s
direct action on VSM, however, is unclear as others have shown insulin promotes
constriction when ECs are removed in isolated vessels (167).

Taken together, these

observations provide strong, but not invariable, evidence o f insulin’s vasodilatory role
and its primarily endothelial basis.
As just alluded to, insulin also demonstrates a distinct vasoconstrictor capacity as
well, particularly in the intact organism. First, insulin causes an activation of the SNS (5;
169; 200) directly by acting on centers in the hypothalamus (137; 153) which typically
leads to increased vasoconstriction in skeletal muscle vasculature.
demonstrate a significant constrictor effect, however (155).

Not all studies

When present, the

vasoconstriction impedes the concomitant vasodilator response, and may in fact be
responsible for the delayed hyperemic response described above (164). Inhibition o f the
action o f the SNS on skeletal muscle vasculature may result in a faster and larger increase
in blood flow. Second, insulin can also cause the production o f endothelin-1 (ET-1) from
ECs (61; 141; 194) and upon binding to the ET-1 receptor type A on VSM cells, ET-1
acts as a vasoconstrictor (126).

This concomitant production o f ET-1 can counteract

insulin’s vasodilatory effect. Thus, inhibition of ET-1 vasoaction, through ET-1 receptor
blockade, enhances the in vivo and in vitro vasodilating effects of insulin (31; 60; 61;
193).
Despite insulin’s clear vasodilating and modest vasoconstricting abilities, the role
of insulin in lowering blood pressure is unclear, and it is likely that insulin has a minimal
blood pressure lowering effect in healthy individuals (5; 12; 169; 177). This may suggest
that insulin is not important in regular blood pressure regulation.

On the other hand

however, blood pressure is already at a relatively low level in healthy individuals, and
thus any agent, including insulin, might not have significant hypotensive effects. In any
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case, the lack o f effect on blood pressure is not completely understood, but it may be due
to the lack o f a large reduction in systemic vascular resistance, albeit with a larger
concomitant reduction in limb vascular resistance in response to hyperinsulinemia ( 12).
The preceding information has only briefly examined the vasoactive role of insulin.
Several extensive reviews have been recently published providing more detail than is
possible here (6 ; 136).

D. Vascular insulin resistance
As mentioned above, the metabolic syndrome is typically characterized by insulin
resistance, and considering insulin’s traditional role, this is defined as an impaired ability
to reduce the blood glucose concentration. However, if insulin also causes vasodilation,
it could be the case that a decreased insulin-mediated hyperemia is partly responsible for
a decreased rate o f glucose uptake. Indeed, diminished responsiveness to insulin occurs
in the vascular endothelium much in the same way, and at the same time, as it occurs in
skeletal muscle (32; 39; 47; 100; 109; 202). To compound the issue, there appears to be a
selective impairment o f the vasodilator capacity o f insulin, but not o f its vasoconstrictor
actions (60; 61; 100). In a state o f insulin resistance and compensatory hyperinsulinemia,
the balance is shifted in the direction of increased vasoconstriction. This diminishes the
hyperemia response, to skeletal muscle and adipose, following insulin infusion or
following the consumption o f glucose (15; 53).

In fact, it has been observed that in

insulin resistant individuals, consumption of glucose can initially lead to an overall
vasoconstriction response (168), whereas in healthy individuals, vasodilation occurs as
described above.

Furthermore, not only is vascular insulin sensitivity important for

insulin-mediated blood glucose clearance, but impaired vascular insulin sensitivity may
even increase blood pressure (208) which indicates decreased basal vasodilation.

As

described above however, the effect on blood pressure is unclear as other studies have
observed normal blood pressure in states o f decreased vascular insulin sensitivity (194).
In mice with vascular endothelium-specific insulin receptor knock-out, there is a
decreased ability to vasodilate and an increased susceptibility to develop systemic insulin
resistance (194). Also, mice with deficiencies in the vasodilator enzyme endothelial NO
synthase (eNOS) are highly susceptible to developing insulin resistance, further
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implicating the interdependence between metabolic and vascular dysfunction (41; 57;
173). Additional evidence o f this connection is provided by ex vivo studies using isolated
arterial samples. Impaired insulin-mediated vasorelaxation has been observed in small
arterioles (61) and in the aorta o f insulin resistant rats (60; 114; 118). Likewise, the
ability to inhibit vasocontraction is diminished in isolated arterioles from insulin resistant
humans (47). Although it is somewhat unclear whether an improvement specifically in
vascular insulin sensitivity would lead to improvement in metabolic insulin sensitivity or
vice versa, there is some evidence that treatment with insulin-sensitizing agents improves
both simultaneously (136; 150). However, this has not been universally demonstrated as
others have improved metabolic insulin sensitivity without improving vascular insulin
sensitivity (183).

E. Vascular studies in the aorta
For ex vivo analysis o f vascular function, and specifically vasorelaxation and
vasocontraction capability, either isolated arterial sections or cultured cell samples are
most often used. O f these two, using intact vessels can be more appropriate to examine
integrated vascular function due to the availability o f intact cell-cell communication and
o f intact structural and spatial regulation between ECs, VSMCs, and the surrounding
extracellular matrix. One approach is to isolate a vessel, typically an artery, and section it
into short tubes or rings, thereby maintaining the tubular structure o f the vessel.
Contraction and relaxation responses can then be measured using force transducers. In
the earliest experiments, investigators isolated mesenteric and coronary arteries, as two
examples (176), but there has also been a widespread use of the thoracic aorta, probably
due to its ease o f use. When it comes to the arterial network, however, generally the
smaller arteries and arterioles possess greater vasorelaxation and vasocontraction ability
than larger ones. Indeed, the aorta does not vasodilate or vasoconstrict significantly in
vivo, and may relax and contract only marginally in comparison to more distal arteries
(201). The aorta, however, can be made to relax and contract significantly ex vivo, often
by having to use supraphysiologic doses o f agonists. However, this is clearly not an
indication of its physiological function. This does not mean the aorta is o f no use. It is
still used for at least one reason: as mentioned above, the signal transduction pathways

11

regulating VSM tension are also largely involved in regulating other aspects o f vascular
function, such as VSM proliferation and migration, and leukocyte adhesion and
infiltration (117).

The detection o f impaired vasorelaxation, for instance, can be an

indicator o f diminished vascular health in the aorta which is of great importance
considering that atherosclerosis tends to affect the larger conduit vessels more so than the
smaller resistance vessels (2).

1.4 Molecular control of vascular function
A. Endothelial nitric oxide synthase
Perhaps the most important endothelial-derived vasodilator is the free radical gas
nitric oxide (NO).

When NO is produced in ECs, it freely diffuses across the EC

membrane to reach adjacent cells, typically the VSMCs in the arteries and veins. NO
binds to its receptor in VSMCs, the enzyme soluble guanylate cyclase (sGC), which then
becomes activated and produces 5’,3’-cyclic guanosine monophosphate (cGMP) (73; 77;
96). cGMP in turn, mostly binds to and allosterically activates cGMP-dependent protein
kinase (PKG), which then phosphorylates a number o f target proteins eventually leading
to a decrease in VSM contraction, largely through a decrease in cytosolic Ca

and the

inactivation o f the myosin regulatory light chain (75; 165; 181).
NO in ECs is produced almost entirely from the endothelial isotype o f the enzyme
NO synthase (eNOS).

eNOS is o f tremendous importance in EC physiology and its

activity level is a major determinant o f vascular function and health (74). eNOS is a
homodimeric protein with a molecular mass o f about 130-140 kDa, and it catalyzes the
net reaction between L-arginine and O 2 to produce L-citrulline and NO (67; 72). In its
coupled dimeric form, its domains are in the appropriate orientation and all required
cofactors are present to allow the proper transfer o f electrons in the reduction o f O2 (74;
178). When the enzyme is uncoupled however, superoxide is produced instead. Indeed,
the uncoupling o f eNOS, and subsequent superoxide production, appears to be an
important etiological mechanism for oxidative stress and endothelial dysfunction (74).
Coupling o f the eNOS redox reactions is highly dependent on the presence o f the enzyme
cofactor tetrahydrobiopterin (BH 4) (7; 152). Impairment o f BH 4 availability decreases
eNOS coupling and NO production and increases superoxide production (110; 207).
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Decreased coupling o f eNOS may also occur through the competitive enzyme inhibition
via the action o f endogenously-produced asymmetric dimethylarginine (ADMA).
ADMA also binds to the eNOS active site, due to its similar structure to L-arginine, but
eNOS cannot act on it to produce NO (19; 190). As ADMA concentrations increase, it
competes against L-arginine for the active site, and therefore decreases the production of
NO, while increasing superoxide production.

The highly conserved and ubiquitous

chaperone protein heat shock protein (Hsp) 90 may also be responsible for the proper
coupling o f eNOS, and so when Hsp90 is activated, it couples eNOS which leads to
increased NO production and decreased superoxide production (80; 142; 151). Hsp90
can thus be thought o f as a pro-vasodilation molecule, and indeed increases vasodilation
and blood flow in response to a number of stimuli (8; 80; 142; 216). The role o f Hsp90
in controlling eNOS will be further examined below.
In addition to Hsp90, a second major protein-protein interaction that regulates the
activity o f eNOS is its binding to caveolin-1. This binding appears to serve one major
purpose: the inhibition o f eNOS activity (56; 81). Calmodulin (CaM), on the other hand,
when bound to Ca2+, activates eNOS. Ca2+ binds to CaM to activate it, and interestingly
the binding o f CaM to eNOS displaces it from caveolin-1 and thereby removes its
inhibition (22; 26; 131). eNOS is also regulated by phosphorylation. There are a number
o f known phosphorylation sites on eNOS which cause both activation and inhibition, and
likewise there are a number o f different protein kinases and phosphatases which regulate
these attached phosphates. For instance, eNOS is phosphorylated at threonine 495 by
protein kinase C (PKC) and adenosine 5’-monophospate-dependent kinase (AMPK)
which causes its inactivation (35; 68; 132). Conversely, one o f the best characterized
phosphorylation sites serine 1177, which is phosphorylated by protein kinase B/Akt,
protein kinase A and also AMPK, causes the activation o f eNOS (28; 35; 54; 76; 132). It
is important to note that there is complex interdependency between the different
mechanisms of eNOS regulation. For instance, Hsp90 not only enhances NO production
through coupling of eNOS, but perhaps more importantly it also serves as a scaffold for
Akt to mediate the activating phosphorylation at SI 177 (70). Furthermore, it is important
to note that full activation of eNOS requires a number o f these mechanisms working in
conjunction.
y

Phosphorylation at SI 177 may activate eNOS, but without the proper
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coupling, it may simply cause an increased production o f superoxide and not NO.
Lastly, eNOS function can be regulated on a more long term scale by altering its
expression level and therefore total eNOS protein content. Environmental stimuli often
result in changes in eNOS protein content, which presumably means a change in basal
and stimulated NO production (11; 171; 188).

eNOS protein expression is regulated

through several transcription factors including nuclear factor

kB

which upregulates

expression (44; 87), and the Forkhead box protein O (Foxo) transcription factors which
may downregulate expression (148).
All o f the mechanisms briefly mentioned here centre around altering eNOSderived NO formation, but it is NO itself that promotes vasodilation. The bioavailability
of NO can also be regulated through means independent o f eNOS, but these will not be
described in more detail here. Furthermore, it is important to remember that VSMCs
determine the vascular tension, and therefore the effectiveness o f NO to produce
vasodilation depends on VSM responsiveness, as well as the integration o f a number of
different vasodilating and vasoconstricting stimuli.

The preceding information is an

extremely brief examination o f the regulation o f eNOS and there are numerous other
mechanisms involved, such as extra protein binding partners, extra phosphorylation sites,
and intracellular localization. The following reviews may be examined for more in-depth
information (11; 66; 75; 84; 106).

B. Multiple roles o f Hsp90 in eNOS activation
As mentioned, Hsp90 physically interacts with eNOS to enhance the production
NO. Hsp90 is a highly conserved, and highly abundant, molecular chaperone protein. It
assists in promoting and maintaining a particular three-dimensional structure o f protein
complexes.

Chaperone proteins, such as Hsp70, often assist in the proper folding of

nascent proteins, refolding o f denatured proteins, and protein trafficking and these
functions are relatively non-specific.

Hsp90 on the other hand has highly specific

binding partners, known as client proteins, with which it typically interacts. Furthermore,
Hsp90 not only assists in the proper assembly o f protein complexes but, as is the case
with eNOS, regulates the function of these client protein complexes. With eNOS, Hsp90
assists in the coupling o f the eNOS monomers (151). Not only does Hsp90 bind to eNOS
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to increase NO production in response to stimuli such as shear stress, VEGF, and
histamine (80), but there is a basal level o f Hsp90 bound to eNOS in unstimulated ECs
( 8; 10).

The promotion of eNOS-Hsp90 complexes, in response to shear stress for

instance, appears to depend on tyrosine phosphorylation, possibly o f Hsp90 itself (58;
192).

Hsp90 also appears to function as a scaffolding protein, allowing Akt to

phosphorylate eNOS at SI 177, and potentiating the effect o f CaM in displacing eNOS
from caveolin-1 (70; 185).
production.

Thus Hsp90 ensures both eNOS activation and NO

Hsp90, via its scaffolding function, allows the transition from Ca2+-

dependent to Ca2+-independent activation in response to stimuli (11; 23). In essence,
extracellular stimuli, such as VEGF, initially cause the activation o f eNOS through a
transient increase in cytosolic Ca2+ concentration.

Hsp90 then recruits Akt to cause

phosphorylation o f eNOS at SI 177, resulting in its continued activation in the absence of
the increased Ca2+ concentration. Lastly, there is some evidence that Hsp90 also protects
eNOS from degradation by calpain (9).

Due to the increase in intracellular Ca

2+

concentration in response to a number of stimuli, calpain activity increases, and without
protection via Hsp90, eNOS would be degraded.

C. Endothelial insulin signalling
Endothelial cells contain constitutively expressed membrane-bound insulin
receptors (IR) and are capable o f responding to extracellular insulin (220). Unlike the
classical target cells o f insulin that regulate energy homeostasis, ECs respond to insulin to
help regulate vascular homeostasis. However, the signal transduction pathways activated
in ECs and in classical target tissues, such as skeletal myocytes, hepatocytes, and
adipocytes, are quite similar. The IR is a tyrosine kinase, and upon the binding of insulin,
is autophosphorylated at several o f its tyrosine residues in its cytosolic subunits (18; 113).
Tyrosine

phosphorylation

initiates

several

signalling

cascades

involving

many

intermediate factors that can also be activated through other receptor signalling pathways.
The presence o f common signalling factors between different receptor signalling
cascades allows interaction and integration of many stimuli, and allows fine-tuning of
cellular responses.
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For simplicity’s sake, the IR signalling cascades can be conceptualized into two
distinct pathways with different outcomes. In ECs, activation of the IR leads to a series
o f subsequent protein phosphorylations involving phosphoinositide 3-kinase (PI3K) and
Akt (136).

Whereas in skeletal myocytes Akt phosphorylation and activation leads

eventually to glucose uptake, in ECs, Akt directly phosphorylâtes eNOS at SI 177,
thereby activating it (54; 76).

Since activation of eNOS works mainly through

phosphorylation, insulin-mediated NO production is termed phosphorylation-dependent
and Ca2+-independent.

Evidence o f this mechanism is seen in studies in which Akt-

mediated SI 177 phosphorylation is inhibited. In these cases insulin is almost entirely
prevented from producing NO (134; 219).
confirmed by utilizing Ca2+ chelators.

Furthermore, its Ca2+-independence is

The lack of Ca2+ action had little impact on

insulin-mediated eNOS activation (134).

Furthermore, insulin does not result in

significant increases in EC Ca2+ concentrations also suggesting a Ca2+-independent
mechanism (93).
Long-term activation o f the PI3K-Akt pathway also results in increased eNOS
expression (65; 108) which potentially leads to enhanced basal NO production and
enhanced responsiveness to a given concentration of insulin, or any other eNOSdependent agent. As mentioned above, the importance o f Hsp90 in ensuring production
of NO and in facilitating the phosphorylation o f eNOS by Akt is important. However,
little evidence exists demonstrating the effect o f insulin on Hsp90-eNOS-Akt complex
formation. Takahashi and colleagues (185) found that insulin causes Hsp90-eNOS-Akt
complex formation and that inhibition o f Hsp90 inhibits the insulin-mediated eNOS
activation.

Interestingly, it has been suggested that the formation of this complex is

physiologically important in insulin signalling, as the activation o f Akt alone is not
sufficient to cause eNOS activation. The hormone platelet-derived growth factor (PDGF)
also activates Akt in ECs but does not cause the association of Hsp90 and eNOS or the
activation o f eNOS (134; 185).

Lastly, there is some evidence that insulin can also

produce prostacyclin from ECs, and prostacylcin is a known endothelial-derived
vasodilator (136). However, little is known o f the signalling mechanisms leading to its
production or its contribution to insulin-mediated vasodilation, and it will not be
discussed further here.
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The second, conceptualized, signalling cascade o f the IR involves the small
monomeric G protein, Ras, and extracellular-signal-regulated kinase (ERK) (71; 149).
This pathway will not be explored in much detail here, but briefly, it results in the
production o f ET-1 which, as noted earlier, opposes the vasodilator function o f NO.
Long term activation o f this pathway also regulates cell-cell and cell-matrix adhesion
(135) and thus may be important for regulating inflammatory processes present in
vascular disease.

Importantly, since insulin can cause both vasodilation through the

eNOS pathway and vasoconstriction through the ERK pathway, the balance o f both
factors determine the eventual outcome of insulin stimulation.

D. Impaired IR signalling in insulin resistance
As discussed above, in states o f systemic insulin resistance, where there is a
decreased effectiveness o f given insulin concentrations to cause blood glucose removal,
there is also decreased insulin responsiveness at the level of the endothelium. In ECs,
there are several mechanisms for the downregulation o f IR signalling. Like in skeletal
myocytes, these include increased serine phosphorylation o f insulin receptor substrate 1
(IRS-1) (82; 102; 116), leading to diminished activation o f PI3K.

The numerous

mechanisms promoting vascular insulin insensitivity lead eventually to decreased
activation o f eNOS, and thus decreased insulin-mediated vasodilation as described above.
It is well known that in states o f systemic insulin resistance, such as in T2DM,
there is decreased eNOS activation in response to a number o f stimuli and not just to
insulin (25; 125; 186). This fact presents a difficulty in establishing the mechanisms for
decreased-insulin mediated vasodilation in insulin resistance. Is it really decreased IR
signalling, or is it a general impairment o f eNOS function?
Interestingly, in a state o f insulin resistance, there is a specific downregulation of
IRS-1 and PI3K signalling pathways. However, activation of the Ras/ERK pathway is
typically not affected to the same degree, if at all (83).

Since there is a level of

interaction between these two IR pathways, a decrease in one can lead to an increase in
the other (135).
decreased

Furthermore, in insulin resistant states, the body compensates for

glucose

removal

by

enhancing

insulin

production,

resulting

in

hyperinsulinemia. The consequence in ECs is a hyperactivation of Ras/MAPK and ET-1
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activation, which disrupts the balance between constriction and dilation.

Thus, the

problem o f a diminished NO production is exacerbated by an increased production of ET1.

In essence, not only is the vasodilatory capacity of insulin diminished but its

vasoconstricting capacity is increased, and indeed in individuals with insulin resistance,
increased ET-1 concentrations are found (145; 146). Lastly, this discussion has focused
on the effects of vascular insulin resistance on eNOS and vasodilation, but as described
above, the mechanisms regulating vasodilation/vasoconstriction and other factors
determining vascular health overlap.

Indeed, the Ras/MAPK insulin pathway, when

upregulated in response to hyperinsulinemia, results in enhanced adhesion protein
expression (135), which is a prominent factor for enhanced vascular inflammation.

1.5 The role of exercise
A. Exercise improves endothelial function
The beneficial effect o f performing regular exercise on cardiovascular health has
been well documented (105; 140). However, there is still great difficulty in explaining
the mechanisms by which exercise produces its beneficial effects. That being said, there
are a number o f systems and mechanisms that have been identified as being affected by
performing exercise, and it is likely that all of them are affected in concert to enhance
cardiovascular health. Specifically for the focus of this study, exercise training has been
shown to be beneficial for endothelial function (11; 209).

Exercise increases

endothelium-dependent vasodilation (51; 204), and decreases inflammatory processes
(115; 158; 214), which together decrease the progression of major vascular diseases such
as atherosclerosis. Conversely, the lack of exercise, or physical inactivity, promotes the
opposite and increases the rate o f progression of endothelial dysfunction ( 111; 182).
There are a number o f mechanisms by which exercise may exert its beneficial
effect on endothelial function. For instance, exercise can increase the fluid shear stress.
In brief, as blood flows through vessels, a certain amount of “friction” occurs between the
endothelium and the blood itself. This results in a mechanical stress that can be detected
by ECs and is proportional to the blood velocity. The healthy endothelium responds to
shear stress by activating eNOS and producing NO to cause vasodilation (69; 80), and
over a longer period o f continued activation, the endothelium increases eNOS expression
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(11; 156; 212). During whole body exercise, cardiac output increases to varying degrees
depending largely on the degree o f increased metabolic demand.

Increased cardiac

output can result in increased blood velocity at certain sites in the arterial system and thus
increased NO production. Including a number o f other EC alterations that will not be
explored here, enhancement o f eNOS function, through exercise-mediated increased
shear stress, can itself lead to improvements in agonist-induced vasodilation. As per the
purpose o f this study, exercise may therefore improve insulin-mediated vasodilation
through a general improvement in NO production and function.

B. Exercise-induced heat shock protein-mediated protection
Exercise has also been demonstrated to increase the activity of HSPs in a number
o f different tissues (89; 91; 121; 138). In general, the function of HSPs is enhanced in
response to cellular stress and they serve to restore cell function.

They mostly

accomplish this through their chaperoning function. In the presence of stress, induced
through factors such as hyperthermia and oxidative damage, many proteins unfold and
lose their proper function. HSPs detect unfolded proteins and typically work to refold
and stabilize them (17; 63). Furthermore, if HSPs are present in high amounts prior to
the introduction o f a particular stress, they can function to mitigate the extent of damage
in a phenomenon known as preconditioning (122; 143; 174). Several types o f HSPs exist
and they each have their set o f client proteins that they bind to. Furthermore, many
HSPs, while retaining their inducible nature, are also active even in unstressed
conditions, and assist in the proper functioning o f the cell (63). As discussed above,
Hsp90 is active in unstressed conditions, and in the context o f endothelium-mediated
vasodilation, Hsp90 works to enhance the production o f NO (80). Hence, it may be
hypothesized that if Hsp90 activity were to be enhanced through chronic exposure to
stress such as exercise, ECs would not only be protected from further stress, but would
have enhanced eNOS function and NO production.
Exercise may induce the activity o f HSPs through a number o f mechanisms,
which are incompletely understood. One potential mechanism is that exercise results in
increased core body temperature which increases as the intensity and duration o f exercise
increases (89; 121; 138).

Increased body temperature is well known to induce HSP
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activity and is indeed the reason for their name.

However, exercise-induced

hyperthermia is not the only factor involved in inducing the HSPs. Indeed, it has been
demonstrated that HSPs can be induced by exercise in the absence o f any significant
increase in body temperature (92; 175) or by mechanisms not relying on hyperthermia
such as glycogen depletion (62).

These effects are likely HSP- and tissue-specific.

Exercise may also increase the production o f reactive oxygen species (ROS) (129; 191),
possibly due to a mismatch between oxidative metabolism and oxygen delivery. ROS
causes cellular damage and it is possible that HSPs can be induced in this maimer (64;
101). As for the purposes o f this study, little is known about the influence of chronic
exercise on the induction o f Hsp90 in the vasculature. Harris and colleagues (91) found
that long term exercise training led to an increased eNOS-Hsp90 interaction in the soleus
muscle.

Considering that eNOS mostly resides in ECs, it is likely that the increased

soleus eNOS-Hsp90 interaction occurred in the muscle micro vasculature; however this
was not explicitly demonstrated. In the aorta however, McAllister and Price (128) did
not find an increased eNOS-Hsp90 interaction following long term exercise training.
Certainly more research is needed to shed light on this discrepancy. If indeed exercise
exerts some o f its beneficial effects through the induction o f HSPs, and in particular by
inducing the interaction o f eNOS and Hsp90, then the improvement in insulin-mediated
vasodilation is due to a general improvement in eNOS-dependent vasodilation. In other
words, not only would insulin-mediated vasodilation improve, but it could be that any
vasodilatory response depending on the action o f eNOS would be improved.

C. The role o f exercise in insulin resistance
It is generally observed that the incidence of the metabolic syndrome is lower in
individuals participating in regular exercise.

There appears to be a dose-response

relationship with exercise and disease incidence or severity (105; 144).

In an acute

setting, exercise enhances glucose uptake and insulin sensitivity in skeletal muscle (94;
99; 159).

However, exercise does not seem to directly enhance signalling through the

proximal IR pathway which makes the exercise-mediated glucose uptake insulin
independent (85; 210).

The positive effect o f long term exercise training per se on

insulin sensitivity is somewhat unclear (52). Studies have shown opposing results in that

20

exercise training in the absence o f weight loss may (48) or may not provide lasting
enhancements of insulin sensitivity (170), but likewise, weight loss in the absence of
aerobic exercise training may not improve insulin sensitivity either (161). Most of the
work demonstrating this effect o f exercise has been done in skeletal muscle and less
evidence exists for the reversal o f insulin resistance in vascular tissue. Li and colleagues
observed that long term swim training in rats largely reversed aging-associated vascular
insulin resistance (118). However, as ACh-mediated vasodilation also improved, it is
unclear whether exercise specifically enhanced insulin signalling. Mikus and colleagues
observed that voluntary free wheel running also elevated insulin-mediated vasodilation
(133). In vivo, exercise training results in enhanced insulin-mediated muscle blood flow
(50).
The mechanisms by which exercise enhances insulin sensitivity are not
completely understood.
signalling pathways.

As mentioned, exercise does not appear to directly affect IR

Alternatively, exercise may enhance insulin sensitivity via the

upregulation o f HSPs, but this has yet to be directly tested. It has been observed that
hyperthermic treatment, and Hsp72 upregulation specifically, increases whole-body
insulin sensitivity (37; 88). As alluded to, perhaps the most potent way exercise enhances
insulin sensitivity is through the reduction o f body fat mass. Increased adiposity is one of
the major causes o f impaired insulin signalling, and as per the purpose of this study, it
impairs insulin-mediated vasodilation (45; 136).

D. Exercise training and sedentary living as independent factors
Lastly, there is an important consideration that should be made when discussing
the beneficial effect o f exercise.

In essence, the question should be asked whether

exercise training enhances function or whether it restores a diminished function to its
normal or naturally defined level.

Conversely, being sedentary can be considered an

unnatural state and it may be that sedentary living causes dysfunction (20; 127). Of
course, this point o f view completely depends on determining what is “normal”, and so
the argument is not indisputable. Alternatively, others have recognized that sedentary
living and exercise training are separate activity patterns each affecting the progression of
disease independently (90). Whereas sedentary living involves prolonged participation in
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activities such as television watching, exercise training often involves regimented
programs and requires significant metabolic demands for discrete periods at a time. The
degree to which an individual engages in each activity pattern may be important and it is
likely that there are complex interactions between the amount o f time spent being
completely sedentary and the time, intensity and type o f exercise training in regards to
the risk o f developing CVD (90; 95). For the purposes of this study, the effect o f a
sedentary lifestyle, comparable to the lifestyle o f a typical adult office worker in a
modem urban setting, will be examined. This issue is important since there is a large
proportion o f individuals in modernized societies who, other than performing physical
activity at an intensity comparable to walking a dog every day, are quite sedentary (55;
107).

1.6 Purpose and hypotheses
The major purpose o f this study was to examine the effect of long term sedentary
living on the progression o f insulin resistance in rats.

In addition, this investigation

aimed to assess whether long term sedentary living would also result in vascular-specific
insulin resistance. A minor component o f this latter objective was to determine whether
vascular-specific insulin resistance coincided with endothelial dysfunction, as determined
by a diminished vasodilatory response to ACh.

Furthermore, given the evidence that

Hsp90 enhances NO production, a third major purpose was to examine the relationship
between vascular responsiveness and the eNOS-Hsp90 interaction. Lastly, the effect of
regular, short duration, low intensity treadmill exercise on the prevention o f insulin
resistance and its potentially associated adaptations was investigated. Importantly, the
performance o f low intensity exercise fulfilled two purposes. First, the performance of
exercise was intended to prevent complete physical inactivity and not intended to result
in improvements o f aerobic capacity. Second, low intensity exercise mimics the type of
exercise performed by a typical adult in modernized societies. It was hypothesized that
sedentary living would result in insulin resistance, impaired vascular responsiveness to
insulin, and a decreased eNOS-Hsp90 interaction. However, the regular performance of
short duration, low intensity exercise would prevent these changes.
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CHAPTER 2
2.1 Introduction
It is now well known that the metabolic syndrome leads to significant increases in
the risk of cardiovascular disease (CYD). This includes both disease o f the heart, like
pathological hypertrophy and heart failure, and disease of the vascular system, like
atherosclerosis. These diseases pose a major threat to longevity and the quality of life
and thus it is important to study both the mechanisms of disease progression and its
treatment and prevention.

Major CVDs, and the metabolic syndrome itself, are very

complex and involve many factors working both to promote and to reverse each
condition. The metabolic syndrome has been defined by a number o f health organizations
(1-3) and is characterized by several common CVD risk factors. These include insulin
resistance and dyslipidemia (14; 33).

O f particular interest in this study is the

dysfunction o f the vascular system as a consequence o f developing insulin resistance.
The arterial system is charged with the supply and distribution o f blood to the
body and different segments o f the arterial tree have specific adaptations in order to
accomplish this. Particularly in the muscular resistance arteries, blood vessels have the
capability to dilate and constrict in response to a variety o f stimuli, thereby controlling
blood flow and delivery. In vascular disease, this functionality is altered, leading to a
variety o f problems. One of the earliest problems is endothelial dysfunction, which is
often considered to be the root o f further complications like atherosclerosis (7; 8; 58).
Although once thought to be a passive barrier, the vascular endothelium is largely
responsible for causing vasodilation in response to chemical and mechanical stimuli (4;
22; 23). Endothelial dysfunction can be simply defined as a diminished vasodilatory
response.
In regards to the development o f endothelial dysfunction, a major associated
factor is insulin resistance (7; 29). Insulin resistance is defined as an impaired response
of the insulin receptors in the canonical target organs skeletal muscle, liver, and adipose.
Among other effects, the most recognized outcome of this impairment is a decreased
uptake of glucose for a given concentration o f insulin. However, insulin receptors exist
in other tissues, and insulin acts on the endothelium to cause, for the most part,
vasodilation (13; 40; 44; 50).

Likewise, just as insulin resistance occurs in skeletal
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muscle, liver, and adipose tissue, vascular endothelium can become less responsive to
insulin in states o f metabolic syndrome and endothelial dysfunction (9; 28; 31). This
vascular-specific impairment may contribute to the vascular consequences o f insulin
resistance.
Endothelial cells respond to insulin primarily by increasing the production of
nitric oxide (NO) (50; 54). They accomplish this through the activation of the enzyme
endothelial NO synthase (eNOS), largely through its phosphorylation at the serine 1177
residue (16; 21). Regulation of eNOS is extremely complex, and includes transcriptional
regulation, phosphorylation, substrate and cofactor availability, and binding to other
proteins (11; 18). One potential contributor to this regulation is the binding o f heat shock
protein (Hsp) 90 to the eNOS enzyme complex. Hsp90 is a ubiquitous, constitutively
produced chaperone protein, which alters the three-dimensional structure of a protein,
thereby altering its function. When Hsp90 binds to the eNOS complex, it contributes to
the proper coupling o f the eNOS dimer thereby producing NO and not superoxide (43).
It also helps to make eNOS available for phosphorylation by Akt (19) and assists
Ca2+/CaM in displacing eNOS from caveolin 1 (24).

Therefore, impaired insulin-

mediated eNOS activation, resulting in decreased NO bioactivity, may partly be due to
decreased binding o f Hsp90 to eNOS.
The development o f the metabolic syndrome, and particularly insulin resistance,
depends on a complex interaction between genetically-inherited predispositions and
external or environmental influences.

O f the many controllable environmental

influences, one that has recently received attention is the performance of physical
activity. It has been well established that the regular performance o f moderate to high
intensity exercise is beneficial in the prevention and treatment of the metabolic syndrome
and the various CVDs (27). However, the influence o f lower intensity exercise, such as
walking, on CVD prevention is less clear.

Examination of low intensity exercise is

important considering a large proportion o f individuals in western societies perform
exercise at this intensity (27). Conversely, it has also been recognized that sedentary
living increases the rate o f metabolic syndrome and CVD (20). There are indications that
the degree o f physical inactivity may be independent of the performance o f exercise as a
risk factor for developing disease (25).
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The purpose o f this study therefore, was to examine the effect o f sedentary living
on the progression o f insulin resistance in rats. Secondly, this investigation proposed to
assess the concomitance o f impaired vascular responsiveness to insulin in isolated rat
aortic segments and whole-body insulin resistance.

Furthermore, the relationship

between vascular responsiveness and the eNOS-Hsp90 interaction was examined. Lastly,
the effect o f regular low intensity treadmill exercise on the prevention of insulin
resistance and its potentially associated adaptations was investigated.

It was

hypothesized that sedentary living would result in insulin resistance, impaired
responsiveness o f the aorta to insulin, and a decreased eNOS-Hsp90 interaction, and that
the regular performance o f short duration, low intensity exercise would prevent these
changes.

2.2 Methods
Animals and Ethics Approval
The University o f Western Ontario Council on Animal Care approved the use and
treatment o f laboratory animals according to the guidelines o f the Canadian Council on
Animal Care.

Thirty male eight week-old Sprague Dawley rats were obtained from

Charles River Laboratories and housed in standard rat cages with a 12:12-hour light-dark
cycle. Food and water were provided ad libitum. Ethics approval for the involvement of
rats was obtained through the Research Ethics Board o f the University o f Western
Ontario (Appendix B).

Exercise and Sedentary protocols
Twenty rats were randomly divided into two groups: an exercise (E; n=10) group
and a sedentary (S; n=10) group. After being housed for 2 weeks, the rats in the E group
walked on a motorized treadmill at an initial speed of 10 m/min at 0% grade, gradually
increasing to 15 m/min by the second week. They continued to walk at 15 m/min for the
duration of the study. Exercise was performed at approximately 2-4 hours into their dark
cycle, and was performed in the dark. In order to mimic a typical exercise pattern o f
many individuals the rats exercised 4 consecutive days each week for 30 minutes on each
particular session. This regimen was continued for 14-17 weeks, such that rats began
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exercising at 10 weeks o f age and finished at 24-27 weeks of age. Thus, these rats can be
considered mature young adults, comparable to 25-30 year-old humans, at the time o f
sacrifice. At this age, rats, and humans, are normally free of disease. Furthermore, it is
important to outline what is meant by the term “low-intensity exercise”. In humans,
exercise performed at intensities lower than approximately 50% of the maximal rate of
oxygen consumption (VC^max) is typically classified as low intensity, and an example of
such is walking.

In rats however, it is very difficult to assess at what percentage of

V02max exercise is performed. Considering the speed at which rats can exercise, a speed
o f 15 m/min can justifiably be likened to briskly walking and likely falls in the range of
50 - 60% o f VChmax (5). A further consideration is that low intensity exercise does not
normally result in improvements in aerobic exercise capacity. Thus, a failure to cause an
enhancement in aerobic capacity can be taken as an indication of the performance of low
intensity exercise.
Rats in the S group did not exercise. However, they were always placed within
proximity o f the treadmill while the E rats performed their bouts o f exercise.

Body

weights for both E and S groups were measured on each exercise day approximately 2-4
hours prior to the beginning of exercise. Ten additional rats were assigned to a baseline
(B) group. These rats did not exercise and were housed for only 2-4 weeks, such that
they were 10-12 weeks old at the time o f sacrifice. In contrast to E and S rats, these rats
can be considered young post-pubertal adolescent rats, comparable to 13 - 15 year-old
humans. Daily body weights were not recorded for this group.

Fasting Blood Glucose and Serum Collection
Fasting blood glucose concentrations were measured in the E and S groups using
a FreeStyle Lite Blood Glucose Monitoring System once every two weeks on non
exercise days. The first blood glucose measurement was obtained the day immediately
before the first exercise day at week 1 and the last measurement was obtained at week 15.
Animals were fasted for approximately 8 hours before blood glucose measurements were
taken.

Rats were bled from the saphenous vein via needle prick, and blood glucose

concentration, in mM, was measured in a drop o f blood using the FreeStyle Lite
glucometer. Subsequently, approximately 100-200 pL o f blood from the saphenous vein
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was collected into microcentrifuge tubes and immediately placed on ice. Blood samples
were then centrifuged at 4°C for 10 minutes at 1500 g. The supernatant of each sample
was aspirated and placed into a second set o f microcentrifuge tubes, and serum samples
were stored at -70°C for subsequent analysis.

Homeostatic Model Assessment - Insulin Resistance
Serum samples were removed from the -70°C freezer and allowed to thaw on ice.
Insulin concentrations were measured in duplicate using an Alpco Immunoassays Insulin
(Rat) Ultrasensitive

Enzyme-linked immunosorbent assay kit (80-INSRTU-E10)

according to the manufacturer’s instructions. In brief, the standards, positive controls,
and each sample were loaded into their respective microplate wells in duplicate.
Microplate wells were coated with anti-rat insulin antibody. Standards used contained
insulin concentrations ranging from 0.15 - 5.5 ng/mL. Wells were then incubated with
the provided antibody-enzyme conjugate for 2 hours at room temperature on a rotary
shaker at approximately 150 rpm.

Wells were then washed with the provided wash

buffer 6 times, after which the wells were incubated with the provided enzyme substrate
for 30 minutes at room temperature on a rotary shaker at approximately 150 rpm.
Without removing the substrate solution, the provided reaction stop solution was added to
each well. Absorbance at 450 nm wavelength was measured within 30 minutes of the
addition of stop solution using a Bio-Rad iMark Microplate Absorbance Reader. Using
the standards, a linear standard curve was produced from which absorbance values for
each sample were transformed to concentrations, in ng/mL. These concentrations were
then transformed into mlU/L units by multiplying by a factor o f 24.80. Homeostatic
model assessment - insulin resistance was then calculated using both the insulin and
glucose concentrations using the formula: HOMA-IR = (I x G)/22.4, where I is the
insulin concentration in mlU/L, and G is the glucose concentration in mM.

Intravenous Glucose Tolerance Test
Intravenous glucose tolerance tests (IVGTT) were performed in all three groups
1-2 weeks before sacrifice. Rats did not perform exercise on the day of testing. Rats
were fasted for a minimum o f 12 hours and blood glucose concentration was measured as

39

described above prior to glucose infusion. A sterile-filtered glucose solution (50% Dglucose, 0.45% NaCl) was injected into one o f the tail veins in conscious rats such that
each rat received approximately 1 g/kg glucose. Five minutes after the initial glucose
infusion, blood glucose concentration was measured again. A cut-off value o f 12 mM
glucose was used to assess the efficacy o f glucose infusion. Rats not above this glucose
concentration 5 minutes after the initial glucose infusion were returned to their cages and
the experiment was attempted again on a subsequent day. Blood glucose concentrations
were then measured again, as above, at 10 minutes and subsequently at 10 minute
intervals until blood glucose concentrations had decreased to below 6 mM. At this point,
the IVGTT was complete and rats were returned to their cages.

Aorta collection
Rats in the E and S groups were killed during the week after their last exercise
bout, such that a minimum o f 3 days and a maximum of 7 days had elapsed since the last
exercise bout. Furthermore, rats were sacrificed on days ranging from the 25th to the 28th
week o f age. To control for the effects o f aging, rats in the B group were sacrificed on
the 10th and 11th week o f age. Rats were anaesthetized via an intraperitoneal injection of
65 mg/kg pentobarbital sodium and were killed via heart excision. The thoracic aorta, in
addition to any remaining portion o f the aortic arch, along with the lungs, esophagus, and
portions o f the diaphragm, were excised from the body and placed immediately into icecold modified Krebs-Flenseleit buffer (118.1 mM NaCl, 4.7 mM KC1, 1.5 mM CaCh, 1.2
mM KH 2PO 4, 1.2 mM MgSC>4, 11.1 mM D-glucose, 25 mM NaHCC>3, pH 7.4). The
aorta was then quickly but carefully isolated from the other organs, and cleaned of its
surrounding connective and adipose tissue. Great care was taken throughout to avoid
directly handling the aorta or touching its luminal surface. A portion of the aorta just
downstream o f the aortic arch was then sectioned into four 2-3 mm long rings, and
following careful removal of luminal blood clots, aortic rings were used for in vitro
isometric tension studies. The rest of the aorta was also sectioned at arbitrary lengths,
blood clots were carefully removed, and the sections were snap-frozen in liquid nitrogen
and subsequently stored at -70°C for further analysis.
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In vitro isometric tension analysis
Each aortic ring, isolated and prepared as described above, was quickly mounted
onto a GlobalTown Microtech EZ-bath system and placed in 37°C modified Krebs Henseleit buffer continuously aerated with 95% 0 ^ 5 % CO 2. Initial ring tension was
manually adjusted to approximately 1 g, and subsequently increased to approximately 2 g
in 0.5 g increments every 5 minutes. Rings were allowed to equilibrate at 2 g o f tension
for approximately 60 minutes. Fresh buffer was added to organ baths at 30 and 60
minutes. To assess vessel viability, 10' M phenylephrine hydrochloride (PE) was added
to each organ bath followed by 10'7 M acetylcholine chloride (ACh). Vessels attaining a
minimum 2 g o f developed tension following PE exposure were deemed viable.
Likewise, vessels attaining a minimum 70% relaxation from the PE precontraction
following ACh exposure were also deemed viable and used for subsequent experiments.
After PE and ACh washout via four buffer changes, vessels were equilibrated again for
30 minutes. 10'6 5 M PE was added to establish a steady precontraction level after which
cumulatively increasing doses o f either insulin or ACh were added to each organ bath.
Insulin (Novo Nordisk, Novolin®ge NPH) was given at seven concentrations: 0.3, 0.75,
1.5, 2.25, 3, 4.5, and 6 IU/mL. ACh was given at five concentrations: 10'8, 10'7 5, 10'7,
10'6 5, and 10'6 M. A steady level o f relaxation was attained before the addition o f either
agent at the next consecutive concentration.

Both insulin and ACh concentration-

response experiments were performed in duplicate. The PE precontraction was deemed
100% tension, and the relaxation responses were calculated as the percent change in
tension relative to the precontraction.

Citrate Synthase Assay
Immediately following removal o f the thoracic aorta, plantaris muscle was
isolated and removed from both hind limbs and snap frozen in liquid nitrogen. Tissues
were stored at -70 °C until they were used for analysis of the citrate synthase reaction
rate. Without thawing, approximately 50 mg o f muscle sample was homogenized using
an electric homogenizer in a 1:20 mass:volume ratio with homogenizing buffer (100 mM
Tris, pH 8.35). Homogenates were then frozen by placing in -70°C and stored until use.
On experiment day, homogenates were removed from the -70°C freezer and allowed to
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thaw on ice. A portion o f muscle sample was added to the reaction buffer (70 mM Tris,
0.1 mM 5,5’-dithiobis-2-nitrobenzoate, 0.45 mM acetyl-CoA) in a 1:94 volume:volume
ratio. Samples were prepared and measured in duplicate. Blank samples (i.e. the reaction
buffer without muscle homogenate) were placed in the sample and reference chambers of
a Beckman DU-640 Spectrophotometer and absorbance was measured at 412 nm
wavelength. Muscle samples, diluted in reaction buffer, were then warmed to 30°C by
placing them in a heated water bath. Oxaloacetate was added to each sample to a final
concentration o f 0.5 mM and absorbance at 412 nm wavelength was immediately
measured continuously for 1 minute. The rate o f change in optical density (AOD/min)
was obtained and the citrate synthase reaction rate was calculated by using the formula:
CS = ((AOD/min)/(13.6))/P, where CS is the rate of citrate synthesis in mM/min/mg
protein, and P is the total protein concentration as determined by the Bradford protein
assay (6).

Aorta preparation
Approximately 150 mg o f frozen aorta was homogenized using a glass-glass
homogenizer in a 1:5 mass:volume ratio with homogenizing buffer (25 mM Tris, 150
mM NaCl, pH 7.2).

Aortic samples were homogenized at approximately -20°C with

consistent pestle strokes for 4 consecutive minutes. Homogenates were then transferred
to microcentrifuge tubes and placed on ice for a minimum of 20 minutes. Samples were
then centrifuged at 3,000 rpm at 4°C for 20 minutes, and the supernatant was collected.
Without freezing, protein concentrations o f each sample were determined using the
Bradford protein assay (6). Sample used for co-immunoprecipitation was never frozen
and used immediately following protein concentration measurement.

The rest o f the

homogenate was stored at -70°C for subsequent protein analysis via Western Blotting.

Co-immunoprecipitation
Equal amounts o f total protein (300 pg) from each homogenate were added to
microcentrifuge tubes. Volumes in each tube were topped up with homogenizing buffer
to equalize volumes such that the final protein concentration o f each sample was
approximately 0.67 pg/pL. Co-immunoprecipitation was performed in duplicate for each
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sample. Samples were never vortexed and were kept on ice for the entire protocol unless
otherwise stated. Agarose-conjugated anti-eNOS antibody (Santa Cruz sc-654 AC, rabbit
polyclonal) was then added to each tube with a dilution ratio of 1:15, and tubes were
incubated overnight with gentle agitation at 4°C.

The following day, tubes were

centrifuged at 14,000 g for 20 minutes at 4°C. Supernatants were removed and placed
into new microcentrifuge tubes for storage. Supernatants were not discarded and tested
for immunoprécipitation efficacy via Western blotting.

Great care was taken to not

remove or disturb the pellet when aspirating the supernatant. Wash/homogenizing buffer
was added to each tube, tubes were shaken, and then centrifuged again at 14,000 g for 5
minutes at 4°C.

The supernatant was carefully removed and discarded, and both

homogenizing buffer and modified 2X Laemmli sample buffer (125 mM Tris, 20%
glycerol, 4% SDS, 10% P-mercaptoethanol, 0.25% bromophenol blue, pH 6.8) were
added to each tube in a 1:1 ratio. Samples were subsequently vortexed and heated at just
less than 100°C for 10 minutes. Tubes were once again centrifuged at 10,000 rpm for 10
minutes at room temperature. The supernatant, now containing eNOS and its binding
partners, was transferred to a new microcentrifuge tube and stored at 4°C for subsequent
Western Blotting analysis. The pellet was discarded.

Western Blotting
Previously-homogenized samples were thawed on ice and topped up with
homogenizing buffer to equalize protein concentrations between different samples.
These equalized samples were mixed with modified 2X Laemmli sample buffer in a 1:1
ratio, and subsequently heated at just less than 100°C for 10 minutes. Equal volumes and
protein amounts (30 pg) o f each sample were loaded into polyacrylamide gel wells. For
co-immunoprecipitation samples, 30 pL o f each sample was loaded into polyacrylamide
gel wells.

Western Blotting was performed in duplicate for each sample.

A human

endothelial cell lysate (BD 611450), which served as a standard, and a molecular weight
marker (BioRad 161-0376) were also loaded onto each gel.

Electrophoresis was

performed and proteins were separated by running through a 6% polyacrylamide gel.
Proteins were electrophoretically transferred to a nitrocellulose membrane and
membranes were blocked with 5% non-fat dry milk (BioRad 170-6404) in Tween-Tris
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buffered saline (TTBS; 10 mM Tris, 100 mM NaCl, 0.1 % Tween-20, pH 7.5) for 1 hour
at room temperature. Membranes were washed in TTBS once for 5 minutes and were cut
into top and bottom portions divided at approximately 110 kDa. Top membrane portions
were incubated with primary antibody specific for eNOS (mouse monoclonal anti-eNOS
IgG, BD 610297, 1:2,000), and bottom portions were incubated with primary antibody
specific for Hsp90 (mouse monoclonal anti-Hsp90 IgG, BD 610418, 1:2,000). Primary
antibodies were diluted in 2% non-fat dry milk in TTBS. Membranes were incubated
with primary antibody overnight at 4°C.

The next day, membranes were washed in

TTBS (3x10 min) and incubated with horseradish peroxidase-conjugated secondary
antibody specific for mouse IgG (goat anti-mouse IgG-HRP conjugate, BioRad 1706 5 1 6 ,1 :5,000) diluted in 2% non-fat dry milk in TTBS. Membranes were incubated for 1
hour at room temperature.

Membranes were washed again in TTBS (3x10 min) and

exposed to a luminol-based chemiluminescent substrate (BioRad WestemC Enhanced
Chemiluminescent Kit, 170-5070). Protein bands were visualized and captured on digital
camera using a BioRad Chemidoc XRS imager and optical density was quantified using
BioRad Quantity One software.

Optical density was normalized to the appropriate

standards. Hsp90 band optical density from co-immunoprecipitation samples were also
normalized to the eNOS band optical density o f the corresponding sample.

Lastly,

selected membranes were stained with Ponceau S to get an indication of equal loading
across the samples. A representative image o f a Ponceau S-stained membrane is shown
in Appendix C.

Data Analysis
Body weight, biweekly blood glucose and insulin concentrations, HOMA-IR
values, and IVGTT blood glucose concentrations were compared using a mixed-model
two-way analysis o f variance (ANOVA) and Tukey’s post-hoc test. The group effect was
always a non-repeated measure. Citrate synthase activities, and protein data obtained
from Western Blot analysis were compared using one-way ANOVA and Tukey’s posthoc test.

IVGTT blood glucose concentrations were transformed into the natural

logarithm scale. Area-under-the-curve (AUC) from 0 to 20 min was calculated. Also,
the coefficient of glucose assimilation (K q) was calculated as follows: K g = (([Gjsmin -
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[ G ] 20m in)/1 5 ) * 1 0 0 ,

where [G]5min and [G]20min are the glucose concentrations, in Ln mM,

at 5 and 20 minutes post-glucose infusion. K q values and AUC were compared via one
way ANOVA and Tukey’s post-hoc test. Isometric tension data were compared using a
mixed-model two-way ANOVA and Tukey’s post-hoc test. The concentration effect was
considered a repeated measure. Missing data points in insulin relaxation curves for 3
individuals (n = 2 in E and n = 1 in S) were interpolated using least squares non-linear
regression fitting. For insulin relaxation curves, the slope o f the straight line connecting
% relaxation responses at 1.5 and 6 IU/mL was calculated and compared via one-way
ANOVA with Tukey’s post-hoc test. AUC was calculated for the entire range of insulin
concentrations.

Finally, the Pearson correlation coefficient between the eNOS-Hsp90

ratio and insulin % relaxation AUC was measured. One outlier insulin relaxation curve
in the E group and one outlier Hsp90-eNOS ratio data point in the B group, as determined
by Grubb’s test, were removed from analyses. All data are expressed as mean ± SD and
differences and correlations were considered significant at P<0.05.

2.3 Results
Animal weights and training status
Rats in both long-term groups (E and S) gained weight continuously throughout
the entire study (Fig. 1; P<0.05). At 10 weeks o f age and prior to the commencement of
exercise, rats in the E and S groups did not have significantly different body weights
(396.4 ±23.1 g vs 399.0 ± 18.6 g, respectively). Mean body weights of each group did
not significantly differ at any time point for the duration o f the study. At 24 weeks of age
and after 14 weeks o f exercise or continued sedentary living, body weights were
approximately 55% greater in both groups and averaged 615.9 ± 65.2 g in the E group
and 631.1 ± 47.1 g in the S group.
Plantaris muscle citrate synthase activity also did not significantly differ between
groups (Fig. 2).

In untrained young B rats, the citrate synthase reaction rate from

homogenized plantaris samples was calculated to average 0.21 ± 0.06 mM of citrate
produced per min per mg o f total protein content. Rats in the E group averaged 0. 17 ±
0.04 mM/min/mg and thus did not have an increased citrate synthase reaction rate. Rats
in the S group averaged 0.18 ± 0.04 mM/min/mg.
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Insulin Resistance measures
Fasting blood glucose concentrations taken at biweekly intervals varied in both
the E and S groups but were not significantly different between groups at any time point
for the duration o f the study (Fig.3A). Blood glucose concentrations, which ranged from
a minimum of 3.9 ± 0.6 mM to a maximum of 5.0 ± 0.8 mM, were not significantly
greater at week 14 compared to week 0 in either E or S groups.
Fasting blood insulin concentrations also taken at biweekly intervals were not
significantly different between the E and S groups at any time point for the duration of
the study (Fig. 3B). Insulin concentrations were significantly higher, however, at weeks
8 and 14 compared to week 0 in both E and S groups. Insulin concentrations increased
approximately 104% in the S group from 0.62 ± 0.32 ng/mL at week 0 to 1.26 ± 0.51
ng/mL at week 14 (P<0.05). Likewise, insulin concentrations increased approximately
79% in the E group from 0.68 ± 0.29 ng/mL at week 0 to 1.22 ± 0.52 ng/mL at week 14
(P<0.05). Furthermore, when insulin concentrations were compared as a percent change
from the concentration at week 0, the S group did not experience a significantly greater
increase by week 14 than did the E group (data not shown).
HOMA-IR calculations were performed to assess the combined variation in both
blood glucose and insulin concentrations. In a similar manner to insulin concentrations,
HOMA-IR values did not significantly differ between the E and S groups at any time
point for the duration o f the study (Fig. 4). HOMA-IR values were significantly greater
at week 14 compared to week 0 in both E and S groups. HOMA-IR values increased
approximately 90% in the E group and approximately 104% in the S group from week 0
to week 14 (3.13 ± 0.46 to 5.95 ± 0.64 and 3.00 ± 0.46 to 6.10 ± 1.02, respectively;
P<0.05). Similarly to insulin concentrations, HOMA-IR values in both groups appear to
peak by weeks 6 and 8 (P<0.05), with no further significant increases occurring
afterwards.
Blood glucose concentrations immediately prior to and in the time following an
intravenous glucose infusion are shown in Figure 5. No significant differences in glucose
concentrations between E, S, and B groups were observed prior to glucose infusion (4.7 ±
0.9 mM, 4.3 ± 1.0 mM, and 4.6 ± 0.6 mM, respectively) and glucose infusion increased
blood glucose concentrations similarly in all groups at 5 minutes after the bolus glucose

46

infusion (14.4 ± 3.0 mM, 15.3 ± 3.8 mM, and 13.1 ± 1.5 mM, respectively). To get an
indication o f the ability to reduce blood glucose concentration, the area under the
glucose-time curve was analyzed and compared. However, due to different durations of
the IVGTT for each individual rat, only data up to 20 minutes post-glucose infusion were
considered. Areas under the curves did not significantly differ between the E, S, and B
groups (P=0.061; Fig. 6A). Furthermore, the coefficient o f glucose assimilation (K g) was
not significantly different between the E, S, and B groups either (3.49 ± 1.50,4.46 ± 2.25,
and 4.56 ± 1.20, respectively; Fig. 6B). Kq is another indication o f the ability to reduce
blood glucose concentration and is directly proportional to the absolute value o f the slope
o f the glucose-time curve between 5 and 20 min.

Lastly, although blood glucose

concentrations were not significantly different between groups at 5 min, they were
significantly lower in the younger B group compared to both E and S groups at 10 min
post-glucose infusion (9.5 ± 1 . 4 mM in the B group vs 12.8 ± 1.8 mM and 12.8 ± 3.7 mM
in the E and S groups, respectively; P<0.05).

Vasorelaxation
In isolated thoracic aortic segments and after the establishment o f a steady PEinduced contraction, incubation with insulin produced different concentration-dependent
relaxation responses in the E, S, and B groups (Fig. 7). Representative insulin-mediated
vasorelaxation tracings are shown in Figure 7A. Maximal relaxation levels ranged from
approximately 40 - 52 % o f the initial contraction. Overall insulin-induced relaxation
responses were not significantly different between E, S, and B groups (P=0.062; Fig. 7B).
However, a significant interaction was observed such that vessel tensions were different
between the S and E groups at 4.5 and 6 IU/mL concentrations (38.1 ± 13.3 % vs 24.3 ±
9.3 % at 4.5 IU/mL, and 54.5 ± 12.3 % vs 41.7 ± 10.6 % at 6 IU/mL, respectively;
P<0.05). The S group also had greater relaxation levels compared to the younger B group
at the 0.3 0.75, 1.5 and 2.25 IU/mL insulin concentrations. In fact, as seen in Figure 7,
exposure to low concentrations of insulin in the B group led to a small 6.5 ± 1.9 %
contraction as opposed to relaxation.
Because o f the experimental design, relaxation responses at each insulin
concentration are accumulated on top o f the previous relaxation level attained. When
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comparing two groups, if a greater relaxation response is attained at a low insulin
concentration, and thereafter the rate of change in tension is equal, then the tension will
consistently remain higher for increasing concentrations. Thus, it is important to examine
the rate o f change in tension over changes in concentration. This can be achieved by
examining the slope of the change in tension over the approximately linear portion of
each curve. The rate o f the change in tension from 1.5 to 6 IU/mL was greater in the B
group compared to both the E and S groups (P<0.05; Fig. 8). Slopes for the E and S
relaxation curves were not significantly different.
Exposure o f isolated aortic segments to ACh produced concentration-dependent
relaxation responses in the E, S and B groups (Fig. 9). Relaxation responses were not
significantly different between E and S groups and relaxations reached approximately 96
- 97 % o f the initial contraction. Representative ACh-mediated vasorelaxation tracings
are shown in Figure 9A. Overall ACh-induced relaxation was significantly lower in the
younger B group compared to both E and S groups and was specifically lower at the 10'7 5
and 10"7 M ACh concentrations (27.9 ± 27.9 % vs 65.4 ± 16.1 % at 10'7 5 M and 62.1 ±
28.1 % vs 87.0 ± 9.3 % at 10'7 M for the B and E groups, respectively, PO .05; Fig. 9B).

eNOS and Hsp90
Homogenized thoracic aortic samples contained both eNOS and Hsp90 protein
(Fig. 10). eNOS protein content did not significantly differ between E and S groups, but
was approximately 82% greater in the younger B group compared to the E group
(P<0.05; Fig. 10A).

Hsp90 protein content, however, was not significantly different

between the E, S, and B groups (Fig. 10B).
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Immunoprécipitation o f eNOS revealed a co-precipitation of Hsp90 (Fig. 11).

The

amount o f Hsp90 bound to eNOS relative to the amount o f eNOS precipitated was
approximately 52% greater in the S group than in the E group. However, there were no
significant differences between the groups (p=0.09 in regards to S vs E). Since the S
group tended to have the greatest insulin-mediated relaxation response, and the greatest
Hsp90-eNOS interaction, correlation analysis was performed on these two factors (Fig.

48

12). Least squares regression revealed the following curves in the E, S and B groups,
respectively, where IAUC is the area under the insulin relaxation curve, and HeN is the
Hsp90-eNOS ratio: IAUC = -36.7HeN + 138.3 (r = 0.64), IAUC = -21.8HeN + 190.1 (r
= 0.41), IAUC = -21.4HeN + 128.5 (r = 0.27). When data from all three groups was
pooled, the following curve was observed: IAUC = -10.9HeN + 126.1 (r = 0.18).
However, no significant correlation was observed between the Hsp90-eNOS ratio and the
area under the insulin-mediated relaxation curve in any o f the groups, either individually
or when data from all three groups was pooled.

Week
Figure 1. Weekly rat body weights. Values are mean ± SD. Both E and S groups
continuously gained weight throughout the study. Body weights did not significantly
differ between groups at any time point; n = 9 to 10 per group per time point.
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Figure 2. Citrate synthase activity in plantaris muscle homogenates. Values are
mean ± SD for the rate of citrate production in vitro normalized to the total protein
concentration in plantaris homogenates. The rate of citrate production rate did not
significantly differ between E, S, and B groups; n = 10 per group.
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Figure 3. Biweekly fasting blood glucose and insulin concentrations. A. Glucose
concentrations, expressed as mean ± SD, did not change by week 14 in either E or S
groups and were not significantly different between E and S groups at any time point; n =
10 per group B. Insulin concentrations, expressed as mean ± SD, gradually increased
throughout the study such that the concentrations by weeks 8 and 14 were greater than
concentrations at week 0 in both E and S groups. Concentrations were not significantly
different between E and S groups at any time point; n = 8 to 10 per group per time point,
a = different than week 0, P<0.05.
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Week
Figure 4. Biweekly homeostatic model assessment - insulin resistance (HOMA-IR)
values. HOMA-IR values, expressed as mean ± SD, gradually increased throughout the
study such that the values as early as weeks 6 and 8 were significantly greater than the
values at week 0 in E and S groups, respectively. Values were greater at week 14 in both
E and S groups. Values were not significantly different between E and S groups at any
time point; n = 8 to 10 per group per time point, a = within S, different than week 0,
P<0.05; b = within E, different than week 0.
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Figure 5. Blood glucose clearance rate following an intravenous glucose infusion.
Overall blood glucose concentrations, expressed as mean ± SD, before and after a 0.5
g/kg intravenous bolus glucose infusion, were not significantly different between E, S
and B groups. However, the B group had lower glucose concentration at 10 minutes after
the infusion. No other significant differences between groups were observed; n = 7 or 8
in E per time point; n = 6 or 9 in S per time point; n = 6 or 8 in B per time point, a = B
different than E, P<0.05; b = B different than S, P<0.05.
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Figure 6. IVGTT area under the curve and the coefficient of glucose assimilation. A.
Area under the glucose concentration-time curve from 0 - 2 0 min, expressed as mean ±
SD, as shown in Fig. 5, did not significantly differ between E, S, and B groups; n = 8 in E
and B; n = 9 in S; p = 0.06. B. The coefficient o f glucose assimilation, K g, from 5 - 2 0
min, expressed as mean ± SD, did not significantly differ between E, S, and B groups; n
= 8 in E and B; n = 9 in S.
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Figure 7. Insulin-mediated vasorelaxation. A. Representative insulin concentrationdependent vasorelaxation tracings for E, S, and B groups are shown. Arrows denote the
addition o f cumulatively-increasing concentrations o f insulin as described in the Methods
section. B. Overall vasorelaxation responses were not significantly different between
groups (group main effect - p = 0.06). However, a significant interaction was observed
such that relaxation levels at several individual insulin concentrations, expressed as mean
percent change from the PE-induced precontraction ± SD, were different; n = 7 in E and
S per concentration; n = 10 in B per concentration, a = B different than E, P<0.05; b = B
different than S, P<0.05, c = S different than E, P<0.05.
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Figure 8. Sensitivity to changing insulin concentrations. The rate o f change in aortic
ring tension, expressed as the mean ± SD percent relaxation per unit of insulin
concentration over the 1.5 to 6 IU/mL concentration range, was greater in the B group
compared to both E and S groups. No significant differences were observed between the
E and S groups; n = 8, 7, and 9 in E, S and B, respectively, a = different than E, P<0.05;
b = different than S, P<0.05.
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Figure

9.

Acetylcholine-mediated

vasorelaxation.

A.

Representative ACh
concentration-dependent vasorelaxation tracings for E, S, and B groups are shown.
Arrows denote the addition o f cumulatively-increasing concentrations of ACh as
described in the Methods section. B. Overall vasorelaxation responses were lower in the
B group compared to both E and S groups (group main effect). Relaxation responses at
several individual ACh concentrations, expressed as mean percent change from the PEinduced precontraction ± SD, were different as indicated; n = 10 in E and S per
concentration; n = 8 in B per concentration, a = B different than E, P<0.05; b = B
different than S, P<0.05.
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Figure 10. eNOS and Hsp90 protein content in aorta homogenates. A. Total eNOS
content, expressed as mean ± SD, was greater in the B group compared to both E and S
groups. A representative western blot is shown with bands located above their respective
bars; n = 10 per group, a = different than E, P<0.05; b = different than S, P<0.05. B.
Total Hsp90 content, expressed as mean ± SD, was not significantly different between
the E, S, and B groups. A representative western blot is shown with bands located above
their respective bars; n = 10 per group.
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Figure 11. eNOS-Hsp90 interaction. The level o f eNOS-Hsp90 interaction, expressed
as mean ratio between Hsp90 and eNOS optical densities ± SD, was not significantly
different between groups. A representative western blot demonstrating both eNOS and
Hsp90 in eNOS-immunoprecipitated samples is shown, with bands located above their
respective bars; n = 10 in E and S; n = 9 in B.
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Figure 12. Correlation between the eNOS-Hsp90 interaction and insulin-mediated
vasorelaxation. No significant correlations were observed between the area under the
insulin-mediated vasorelaxation curves and the Hsp90-eNOS ratio and as shown in Figs.
7B and 11, respectively.

66

2.4 Discussion
One o f the most potent risk factors for the development of CVD is the presence of
insulin resistance.

It has been demonstrated in a variety o f populations that the

performance o f regular exercise impedes the development o f insulin resistance and of
CVD.

From a different point o f view however, it is thought that sedentary living

accelerates the progression o f insulin resistance and CVD and that regular exercise
maintains one’s “normal” health status. Consequently, sedentary living is an external
condition promoting the development o f disease.

Previously, our lab has made the

observation that “control” rats, which were cage-confined for their entire 20 weeks of
life, were starting to show indications o f incipient insulin resistance (unpublished
observations). In these studies, rats which trained at moderately high exercise intensities
did not develop insulin resistance. However, the question arises whether performing any
amount or intensity o f physical activity may be beneficial.

The importance of the

intensity o f physical exertion is still being investigated and there are conflicting reports
on just how low the exercise intensity can be while still maintaining its beneficial effects
(57).

This consideration becomes important in the case of many individuals in

modernized societies who live fairly sedentary lives. An average adult may have a desk
job and the only physical activity performed may be daily walks to and from work or at
leisure in the evening. At a young age and in an otherwise normal individual, leisurely
walks are not highly intense bouts o f physical activity. Thus, the first major objective of
this investigation was to examine the effect o f sedentary living on the development of
insulin resistance and it was hypothesized that short-duration, low intensity exercise
would prevent this development.

The findings o f this study do not support this

hypothesis.
In the early stages of insulin resistance, hyperinsulinemia occurs (47) in
compensation for decreased insulin sensitivity.

Thus, the gradual increase of insulin

concentrations (Fig. 3B) without a change in glucose concentrations suggests developing
insulin resistance in both E and S groups.

Furthermore, HOMA-IR has been

demonstrated to be another reliable indicator o f insulin resistance (35). In the present
study, HOMA-IR values approximately doubled by the 14th week in both E and S groups
(Fig. 4). Li and colleagues (32) have observed insulin concentrations in rats similar to
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those observed here, and have also observed an increase with aging. It is interesting to
note, however, that while glucose concentrations are similar in humans and in rats,
insulin concentrations appear to be much higher in rats than in humans. Consequently,
HOMA-IR values reported here are much higher than values typically found in humans
(56).
Although long-term exercise training has been demonstrated to prevent the
development o f insulin resistance (30), 14-17 weeks o f short-duration, low intensity
exercise did not prevent the increase of HOMA-IR in the present study.
Indeed, one difference between this study and other studies is the lack of
sufficient exercise intensity to lead to training adaptations, as was intended.

This is

demonstrated by the finding that the plantaris muscle citrate synthase activity did not
significantly differ amongst groups (Fig. 2).

Furthermore, higher intensity aerobic

training in male rats tends to lead to a lower body weight (41), which did not occur here
(Fig. 1). In other studies, when exercise training is sufficient to increase citrate synthase
activity, improvements in insulin sensitivity are also observed in insulin resistant
individuals (48; 49).

Together with the results of the present study, these findings

suggest that an improvement in muscular or whole body aerobic capacity is a co-requisite
to induce improvements in insulin resistance. This being said however, it is important to
acknowledge that, although it is difficult to determine in a rat, the insulin resistance
observed in this study may not be clinically significant as the results of the IVGTT
suggest.
IVGTT is a second commonly used indicator o f insulin sensitivity. By definition,
in healthy rats, given an intravenous glucose challenge, blood glucose does not typically
reach as high a concentration and it decreases at a faster rate than in an insulin resistant
rat. Although all groups of rats reached similar peak blood glucose concentrations 5
minutes after glucose infusion (Fig. 5), and exhibited similar rates o f decrease o f blood
glucose concentration (Fig 6B), the B group did attain significantly lower blood glucose
concentrations at 10 min after the glucose infusion compared to both the E and S groups.
This could indicate that the B group was able to dispose o f the glucose faster than the
other groups.

If the area under the curve is considered, there were no significant

differences (p=0.06) between groups, and thus overall blood glucose concentration was
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not lower over time in the B group (Fig. 6A). Together, the data suggest most strongly
that there was no apparent decrease in insulin sensitivity in the E and S groups which is
in conflict with the HOMA-IR results. A possible reason for this discrepancy is that
during the IVGTT, the rats in the E and S groups may be releasing more insulin
compared to the B group in response to the same concentration o f glucose. Alternatively,
they may have even had more insulin to begin with considering they had
hyperinsulinemia, as discussed above. This could result in them being equally effective
at reducing blood glucose, but it requiring more insulin to do so. Indeed, it has been
observed that in individuals with early-stage insulin resistance, but devoid of overt type 2
diabetes, insulin concentrations are elevated during glucose tolerance tests with no
significant difference in blood glucose concentration (15; 45). Future analyses should
include an investigation o f blood insulin concentrations during an IVGTT to detect
possible hyperinsulinémie IVGTT profiles. Overall, the above results suggest that the
level o f insulin resistance is minor and in an early stage.
The presence o f insulin resistance accelerates the progression of CVD, and of
particular interest in this study, the development o f endothelial dysfunction (7). One of
the earliest malfunctions that occur in the vascular system may be endothelial dysfunction
(58).

Previous studies have demonstrated the physiological relevance of insulin’s

vasodilatory effect both in vivo and in vitro (17; 31; 32; 44). Additionally, it has been
demonstrated in insulin resistant individuals, that insulin has a much reduced vasodilatory
effect (31; 55), and furthermore, that regular exercise can improve vascular insulin
responsiveness in such individuals (32; 37).

In the present study, to assess insulin’s

vasodilatory effect, the thoracic aorta was isolated and exposed in vitro to various
concentrations

o f insulin.

Insulin

caused

an

overall

concentration-dependent

vasorelaxation response similar to that shown in previous investigations (Fig. 7) (30; 32).
Two methods were used for interpreting the vascular responsiveness to insulin: by
comparing the magnitude o f the overall relaxation in response to each concentration of
insulin, or by comparing the relative change in tension in response to a change in insulin
concentration. It is difficult to determine which particular property is more important so
both will be considered. With the first method, surprisingly, short-duration, low intensity
exercise training did not improve vasodilation, but rather it resulted in slightly lower
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responsiveness.

This is in contrast to the insulin-mediated relaxation responses in

animals exercised at a higher intensity for a similar number of weeks (32) or in animals
exercising voluntarily for many weeks on free wheels (37). Furthermore, this finding
does not parallel the HOMA-IR or IVGTT findings in the present study either. As for
blood glucose management, the S and E rats showed no significant differences, whereas
in the aorta, the exercised rats had slightly lower responses. At the moment no good
mechanistic explanation for this occurrence can be readily suggested.

No published

investigations to the best o f our knowledge have reported a deleterious effect of exercise
on insulin sensitivity, or on endothelial function.
As mentioned above, long term, low intensity treadmill exercise was not effective
at preventing the progression o f insulin resistance, which was contrary to the hypothesis.
These findings do not parallel other long term exercise studies (32; 37). To reiterate,
however, certain aspects of this study separate it from previous work. As per the purpose
o f the study, the intensity o f exercise performed here was relatively low compared to the
majority o f rat exercise training studies. Many studies use speeds up to 30 m/min, which
was twice the speed used in this study. The intensity chosen was based on previous work
that examined oxygen uptake in rats running on a treadmill at different speeds (5). The
exercise intensity chosen here is approximately 50-60% of V02max- Li and colleagues
(32) demonstrated that after long term high intensity exercise training in rats, the
vasodilation response to insulin in the aorta was improved. Mikus and colleagues on the
other hand (37), observed that when obese-prone rats exercised voluntarily on free
wheels, in which they exercised for many hours a day, the vasodilation response to
insulin in arterioles was largely improved. These considerations suggest that an intensity
and/or duration threshold for exercise exists, above which vascular function is enhanced.
Perhaps more difficult to explain than the S group having a greater relaxation
response than the E group is the observation that the relaxation response o f the S group
appeared to be greater than the response o f the B group at the lower insulin concentration
range. This might suggest that, not only was the sedentary group more responsive to
insulin than exercised animals, but the insulin responsiveness had improved with age,
over baseline levels. The second method o f interpreting insulin-mediated vasorelaxation
provides a different conclusion, however. Although the B group may have had an initial

*
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vasocontraction response, leading to an initial tension lower than both E and S groups, by
the time aortic segments had been exposed to the highest insulin concentration, the
relaxation level matched that o f the S group. In other words, the sensitivity to changes in
insulin concentrations was greater in the B group than in the S and E groups (Fig. 8).
This suggests that the B group did not have lower insulin sensitivity than the S group and
may have even had the greatest insulin sensitivity. Furthermore, from this point o f view,
the small differences between the E and S groups disappear as both groups had similar
slopes in their insulin-mediated relaxation curves. This interpretation is in accordance
with the previously discussed changes in HOMA-IR and IVGTT, in which no significant
differences were observed between the E and S groups.
As noted above, insulin produced a small, yet significant, contraction response at
low concentrations in the B group. Although an insulin-mediated contraction response
has been observed in vivo (46), it may be largely due to a sympathetic-induced
vasoconstriction. In vitro, of course, the SNS plays no role, so other mechanisms must
have been engaged. Eringa and colleagues (17) have previously observed that insulin
may cause a vasoconstriction in isolated arterioles. In that study, upon pharmacological
blockade o f endothelin-1

(ET-1), a potent vasoconstrictor, the insulin-mediated

vasoconstriction was abolished. It is possible that a similar mechanism is responsible for
the small vasoconstriction observed in the B group in the present study. However, it is
also important to acknowledge that the magnitude o f the contraction response was a small
6% change, which may not be of much physiological relevance.
Lastly, although there is clear evidence o f the role o f eNOS in the insulinmediated vasorelaxation response (40), the contribution of eNOS-derived NO was not
confirmed in this study.

Therefore, whether the differences in the groups described

above are due to alterations in the activation o f eNOS cannot be directly assessed. An
examination o f the relaxation response in the presence o f an eNOS inhibitor would have
been necessary to determine the potential contribution of impaired eNOS activation.
As mentioned, insulin resistance typically results in endothelial dysfunction.
Therefore, to get a second, more general indicator o f endothelial dysfunction, the
vasorelaxation response to cumulatively increasing doses of ACh was examined in
isolated aortic segments (Fig. 9). ACh is a common endothelium-dependent vasodilator
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that mostly relies on the production o f NO (22). Contrary to the differences in insulinmediated relaxation, ACh-mediated relaxation responses were not significantly different
between the E and S groups. Hence, although the E and S groups were demonstrating
signs o f developing insulin resistance - namely increased HOMA-IR values - this was
not severe enough to cause overt endothelial dysfunction. The fact that ACh-mediated
relaxation remained intact in the E and S groups, while the insulin-mediated relaxation
response may have been diminished, suggests a specificity o f endothelial dysfunction in
that dysfunction may occur in response to some agonists but not to others.

This

interpretation is also in accord with the idea that, although insulin and ACh are both
thought to cause relaxation through the activation o f eNOS, separate signalling
mechanisms are involved in its activation. Insulin has been shown to be dependent on the
phosphorylation o f eNOS on serine 1177 thereby causing its activation (16; 21). The
activation o f eNOS through insulin is not dependent on the influx o f Ca

(39).

Conversely, ACh is thought to activate eNOS through the influx o f Ca2+, and the binding
o f activated Ca2+/CaM to eNOS.

Similar observations have been made in insulin

resistant humans in which forearm blood flow responses to insulin were blunted, whereas
responses to ACh remained intact (51). Similarly, in isolated mesenteric vascular beds
perfusion pressure responses to insulin were slightly blunted in hypertensive rats, but
responses to ACh were not affected (42). Finally, in isolated skeletal muscle arterioles,
vasodilation responses to insulin were highly blunted in obese rats, but responses to ACh
were not significantly affected (37).
It was also observed that the B group appeared to have a lower ACh-mediated
relaxation response than both E and S groups, which was specifically lower at the lower
ACh concentrations. These results are in opposition to other published studies as they
suggest that sedentary living enhanced endothelial function. No adequate explanation for
these results can be put forward at the moment. However, it is interesting to note that
relaxation responses to both insulin and ACh were lower in the B group at the lower
concentrations.
A final objective o f this investigation was to examine the contribution o f the
eNOS-Hsp90 interaction in the development of vascular insulin resistance. As mentioned
above, insulin-mediated vasodilation is largely due to the activation o f eNOS. It has been
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demonstrated that one o f the activators o f eNOS is Hsp90 (18).

However, the

contribution o f Hsp90 to insulin-mediated vasodilation in intact vessels is unclear. A
previous study has also examined the contribution o f the eNOS-Hsp90 interaction in the
activation o f eNOS by insulin in endothelial cell culture (52). In the present study, it was
expected that the degree o f eNOS-Hsp90 interactions would be proportional to the
insulin-mediated vasorelaxation response.
First, the E and S groups did not have significantly different eNOS content (Fig.
10A) which is consistent with the interpretation that low intensity exercise was
ineffective at improving aerobic capacity, insulin sensitivity, or endothelial dysfunction.
Previous studies have shown that more intense exercise training increases eNOS content
(32; 36; 53). Also, the B group had significantly higher eNOS content than the E and S
groups. This is in accordance with the idea that increasing insulin resistance leads to
endothelial dysfunction. Furthermore, whether the decrease in eNOS content observed in
the E and S groups was due to aging is unclear. It has been observed that eNOS content
increases, decreases, or doesn’t change in otherwise healthy older rats (10; 12; 32; 53).
The increased eNOS content in the present study is also in accordance with the finding
that the B group had the greatest slope o f insulin relaxation, and as discussed, perhaps the
greatest sensitivity to insulin. Generally, eNOS content is elevated when responsiveness
to endothelial-dependent vasodilation, in general, is enhanced, and vice versa.

Thus,

decreased eNOS content in the E and S groups may be a herald for impending endothelial
dysfunction. However, an increased eNOS content in the B group cannot explain the
decreased insulin and ACh relaxation levels as described above.

It should be

acknowledged then, that total eNOS content may not necessarily imply eNOS activity, as
observed by others (10; 36).
In contrast to eNOS, Hsp90 content was not significantly different between
groups (Fig. 10B). Hsp90 is a member o f the HSPs, and its activity is thought to be
upregulated by exercise training (26; 36). The lack o f change in Hsp90 content is in
accord with the study by McAllister and Price (36). The reason for the lack of change in
Hsp90 content may again be a result of the exercise intensity not being high enough to
induce the HSPs.

This has previously been demonstrated for another HSP, Hsp70 (38).
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Conversely, aortic tissue may not be as responsive to exercise intensity as is the skeletal
or cardiac muscle examined in the study by Milne and Noble (38).
Finally, the interaction between eNOS and Hsp90 was analyzed via coimmunoprecipitation.

No significant differences were observed between the groups

which was similar to the study by McAllister and Price (Fig. 11) (36). Although no
significant differences were detected, the S group had approximately 50% increased
eNOS-Hsp90 interaction, which may have had physiological consequences. Although
these data do not coincide with a previously published investigation, in which exercise
training results in an enhanced eNOS-Hsp90 interaction (26), they somewhat parallel the
results found when examining the insulin-mediated relaxation responses in the present
investigation.

However, upon correlational analysis, no significant correlation between

the eNOS-Hsp90 interaction and the overall insulin-mediated vasorelaxation response
was observed (Fig. 12). If indeed the eNOS-Hsp90 interaction is important for insulinmediated relaxation, it is not related to the unstimulated eNOS-Hsp90 interaction. Thus,
it is possible that these findings do not truly reflect what occurs in response to activation
by insulin.

Further research would need to examine the eNOS-Hsp90 interaction in

insulin-stimulated vessels.
In conclusion, this study has demonstrated that although a sedentary lifestyle,
and/or aging, may promote the development o f insulin resistance, relatively low intensity
exercise training did not alter the sensitivity to insulin, and may have even blunted
vascular responsiveness. It is important to acknowledge that the impairment observed in
this study is relatively minor.

These findings have implications for exercise training

studies using animal models.

If indeed sedentary “control” animals are becoming

dysfunctional, exercise training may not necessarily lead to improvements, but may just
be preventing, or reversing, dysfunction due to sedentary living back to a “basal” level.
This idea has recently received attention in the literature (34). Future studies should
investigate the effects o f much longer periods of sedentary living on the development of
insulin resistance to see whether the trends observed in this study are supported.
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CHAPTER 3
3.1 Speculations, limitations and future prospects
The present study has found novel results that have been difficult to explain. This
is mostly due to the lack o f other studies finding similar outcomes, and also the lack of
studies examining low intensity exercise. In this study, there are several considerations
and limitations that should be acknowledged in order to present appropriate explanations
o f the numerous results. The first consideration concerns the difficulty in controlling the
exercise intensity performed by the E rats.

The speed o f running was chosen by

referencing previous studies investigating oxygen consumption in exercising rats (2).
However, it is almost impossible to demonstrate how the exercise intensity may have
changed throughout the study. The running intensity equated to approximately 50-60%
o f the predicted V02max in young rats. Considering this, it is also difficult to apply the
present findings to humans. For one, 50-60% o f VC^max may not be very high, but it may
be a high-enough intensity to prevent the development of a number o f impairments (10).
It could be that the prevention o f insulin resistance specifically, however, requires
somewhat higher intensities. Conversely, it must be acknowledged that rats may require
a much higher activity level to receive the same benefits as humans. Furthermore,
because the effect o f sedentary living on insulin resistance wasn’t severe, as discussed in
the previous section, exercise may not have been expected to make much difference. If
indeed exercise works to return or maintain individuals in a “normal”, “healthy” state, as
propounded by Booth and Laye (3), then there may not be a significant role for exercise
in this case. If the rats had been allowed to stay sedentary for a longer period o f time,
perhaps then even low intensity exercise would have produced differences.
O f course, the question arises then, which may be the topic o f further
investigation, as to whether the trend for increasing insulin resistance would continue.
For instance, if these rats had been allowed to exercise and be sedentary for twice as long,
would they have developed significant, indisputable insulin resistance? This point also
brings up an important objection and potential limitation in this study. Aging on its own
is implicated in the development of insulin resistance as well as a number of other
dysfunctions, like CVD. It is reasonable to question whether the increasing insulin
resistance observed here is simply due to the process o f aging, and not really due to
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sedentary living. However, perhaps the issue is more importantly that these rats, and
their sedentary lifestyle, represent a model o f unhealthy aging. By living a sedentary
lifestyle, these rats are experiencing defects in glucose control that would normally be
experienced at a much later age if they had gone through “healthy” aging.
Returning to the issue o f exercise intensity, why exactly intensity is so important
is not completely understood. As mentioned, in studies where muscular aerobic capacity
increased, clear improvements in insulin sensitivity occurred (12; 13). Improvements in
aerobic capacity are accompanied with a plethora o f changes in many systems o f the
body, including changes in the contribution o f fat and glucose metabolism to ATP
production, improved circulatory distribution in skeletal muscles, and increased basal
metabolic rate, among many others. One o f the major cellular adaptations that allow
improved aerobic capacity is increased skeletal muscle mitochondrial content and activity
(7). One consequence o f improved mitochondrial function is that it may allow a greater
utilization o f fatty acids for fuel, which could consequently reduce the storage o f fatty
acids.

Greater fat stores results in a number of alterations, including increased ROS

production and MAPK activation (1; 14). Both o f these may lead to alterations in IR
signalling, such as enhanced serine phosphorylation o f IR substrate 1, which decreases
insulin sensitivity (1). Thus, improved mitochondrial function may prevent the excessive
accumulation o f intracellular fat stores, and maintain insulin sensitivity, but it requires a
high-enough exercise intensity to do so.
It may not necessarily be the case that an improved aerobic capacity is a
requirement for improving insulin sensitivity. It may be that the type o f exercise that
enhances aerobic capacity, also independently improves insulin sensitivity. For instance,
improved aerobic capacity may be accompanied with reduced whole body adiposity. As
above, it has been demonstrated that whole body fat mass and particular body fat
distribution patterns are major etiological factors in the development o f insulin resistance
(6). Thus, a reduction, or favourable redistribution, o f body fat due to exercise training
may alone prevent the development o f insulin resistance. O f course, changes in body fat
are influenced by both activity level and dietary intake. This presents a limitation in this
study. Activity levels and eating habits o f sedentary rats, and even of exercised rats once
they had returned to their cages, were not measured. This data could have added greatly
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to characterizing each group’s trajectory regarding insulin resistance and vascular
dysfunction, and should be considered for future investigations.

In addition, another

limitation is that body composition was never measured in these rats. This too could
have provided important evidence which may have helped to explain why exercise was
ineffective in altering insulin sensitivity.
As mentioned previously, it has been demonstrated that the activity o f the HSPs is
most highly induced at high exercise intensities and not at lower intensities (9).
Furthermore, the induction o f Hsp72 in skeletal muscle has been shown to increase
insulin sensitivity (5). Therefore, improvements in insulin sensitivity, or in other
functions, may depend greatly on exercise intensity and simply the performance o f any
exercise, as a means to avoid complete inactivity, may not be enough to stop age and
inactivity-related changes. Lastly, in regards to improvements in the vascular response to
insulin, there is evidence that shear stress upregulates insulin receptor signalling (8).
Thus, as greater exercise intensity increases cardiac output, shear stress in the aorta might
also increase, resulting in more pronounced effects on vascular insulin sensitivity.
The lack o f sufficiently intense exercise may explain why exercise may have not
been beneficial in the present study.

However, the finding that the insulin-mediated

vasorelaxation in the E group may have been even worse than that in the S group
deserves mention and should be a major topic o f further investigation.

Aside from

similar arguments regarding exercise intensity, another potential explanation for the
vascular dysfunction has been considered. There is some evidence that vasodilation may
be induced by H2O2 (4; 11). Furthermore, H 2O2 is generated by, and plays a role in,
insulin receptor signalling (1). If this is the case, then insulin could have caused
vasorelaxation responses in this study through this alternate pathway. However, it is well
established that H 2O2, which belongs to the family o f reactive oxygen species (ROS),
eventually leads to endothelial dysfunction, inflammation, and a host o f other vascular
problems. ROS are a central etiological factor in most CVDs. It could be that the
sedentary rats were in a very early stage o f endothelial dysfunction at the time of
measurement. It is possible that sedentary rats were producing a greater amount of H 2O2
to increase the level of vasorelaxation, but that this level o f H 2O2 has not caused enough
accumulated oxidative damage to cause evident endothelial dysfunction. Future studies
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could examine the contribution o f H2O2 to vasodilation, if it truly exists in the present
conditions, using catalase or H 2O2 donors for instance.
Other limitations in the present study include the fact that the direct influence of
Hsp90 on insulin-mediated relaxation was not examined. This could be accomplished in
future studies by pre-incubating vessel segments with particular Hsp90 inhibitors, such as
geldanamycin or radicicol, followed by incubation with insulin. If indeed, Hsp90 plays a
role in mediating the insulin-mediated relaxation response, then inhibition of Hsp90
should decrease the level o f vasorelaxation.

Another limitation is that the content of

eNOS, Hsp90, and the eNOS-Hsp90 interaction were measured in unstimulated aortic
samples. Although this data may provide some information regarding the state of the
vessel, it does not necessarily indicate an altered response o f the vessel to insulin. Thus,
it is possible that the results may not be entirely relevant, at least in terms of vascular
insulin sensitivity. Furthermore, the content of the SI 177-phosphorylated eNOS was not
measured, which would more-directly provide evidence for eNOS activation.

Future

studies could determine these molecular markers in vessel segments after exposure to
insulin concentrations. Finally, another limitation is that these molecular markers were
measured in whole aortic homogenates.

Although evidence suggests the majority of

eNOS is found in the endothelial layer, and little is found in the VSM, it is unclear
whether the observed protein contents reflect endothelial changes.

This could

particularly be the case for Hsp90. Since the endothelium makes up only a small portion
o f the mass and volume o f the aorta, any change occurring specifically, and only, in the
endothelium may be obscured by the much larger contribution o f VSM Hsp90.
Determining the changes occurring specifically in the endothelium may be difficult. One
way future studies could partially avoid this limitation is to measure protein contents in
situ using immunohistochemistry.
These limitations notwithstanding, the present study demonstrates several major
findings as discussed in a previous section o f this thesis.

The findings provide the basis

for future investigations involving a more thorough analysis o f the impact o f sedentary
living on vascular function. Future studies may address many o f the limitations outlined
here.

Furthermore, another potential avenue for subsequent investigation is the

characterization o f the effects on other branches o f the vascular network. For instance,
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the effect on smaller skeletal muscle arterioles may be compared to the effects in the
femoral artery. It is important to remember that the results obtained here occurred in the
thoracic aorta, a vessel not highly involved in vasodilation and vasoconstriction in vivo.
Other branches o f the vascular network may be more or less sensitive to alterations in
whole-body insulin sensitivity. Along similar lines, an eventual goal o f such research
should be to ascertain the relevance o f the present findings to the physiology of intact
living individuals.
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APPENDIX A
A l. Vascular Myography Protocol
Pharmacological agents tested:
Phenylephrine (PE), Acetylcholine (ACh), Insulin

Tissues tested:
Aorta

Before you begin
Make sure you have the following materials:
1.5 L o f ddH20 maintained at 37° C in one beaker
0.5 L o f ddH20 maintained at 37° C in one Erlenmeyer flask
Pre-weighed portions of 1) calcium chloride dihydrate (CaCl2-2H20 ) - 0.441 ±
0.001 g
2) sodium bicarbonate (NaHCCh) - 4.201 ± 0.001 g
Pre-made 0.1 M ACh solution in 1.5 mL Eppendorf tube (stored in -20°C freezer)
Small printed 2 mm x 2 mm grid (or graphing paper)

Buffer preparation
1. Turn on heated water pump at the myography system.
2. Prepare the Krebs-Henseleit buffer
a. Wipe down a magnetic stir bar with 70% ethanol and absolutely make sure
all ethanol residue is gone before using it.
b. Place magnetic stir bar into the 2 L (with ddH20 ) beaker and begin to stir.
c. As this is stirring sequentially add the different components:
i. 2 portions o f pre-made modified 1 L Krebs-Henseleit buffer
powder (Sigma K3753)
ii. 1 portion (0.441 ± 0.001 g) o f CaCl2-2H20
iii. 1 portion (4.201 ± 0.001 g) o f NaHCCb
d. Use a pipet to fully wash out all powder residue from each container (use
the buffer itself to wash).
e. Pour warm ddH20 from the Erlenmeyer flask into the 2 L beaker until the
total volume while stirring is just about 2 L.
f. Tip: Check pH with an electronic pH meter if desired. pH should
automatically be at around 7.4 after dissolution o f NaHCCb.
g. Tip: Checking the pH now adds a potential contaminant, so don’t do it if
it’s not necessary.
3. Accurately measure out 2 L o f Krebs-Henseleit buffer with a graduated cylinder,
and pour the final solution into a large 2 L bottle.
a. Optional: You can filter the solution using large Whatman No. 4 filter
paper if desired as you pour it into the 2 L bottle.
b. Tip: You can measure the 2 L o f solution more accurately with a 2 L
volumetric flask, however this is far more difficult to clean and therefore
may eventually lead to impurities in the solution after repeated use.
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4. Place the completed Krebs-Henseleit buffer bottle back into the 37° C water bath.

Washing
5. Prepare approximately 4 L o f ddH20 .
a. Tip: It is very difficult to pour ddH20 into the myography system directly
from a 4 L Erlenmeyer flask or from a 4 L bottle. Therefore, it may be
necessary to make at least two 2 L batches of ddH20 , or even four 1 L
batches.
6. Optional: Check the temperature o f the organ baths with the electronic
thermometer.
a. Tip: this can also function to clean off the thermometer since there should
be 10% acetic acid in each organ bath
b. If the temperature is not within the appropriate range (36.5 - 37.5° C), then
make a slight adjustment to the heated water pump setting.
7. If 10% acetic acid was previously used, flush out the acetic acid from the
myography system.
a. Either immediately before or during the flush-out, make sure to turn on the
gas so that you push out any residual acetic acid from the gas lines. Turn
off the gas and fully release the pressure after the first 2 L flush with
ddH20 .
b. Flush the acetic acid through each individual organ bath, and the “reservoir
collection” tube, one at a time.
c. Make sure that as you flush each organ bath, the flow rate is high enough
that the fluid reaches up just to the point of overflowing.
d. Flush through each organ bath with approximately 125 mL of fluid on each
wash (this is approximately the volume o f each waste cup).
e. To remove the last bit o f fluid from the reservoir, you have to tip it as much
as possible in the direction o f flow. Tip: There will usually remain a small
amount o f fluid, but this can be washed out by the following 4 L o f ddH20 .
8. Perform two 2 L flushes o f the reservoir, tubing, and organ baths using the 4 L of
ddH20 previously prepared.
a. Perform 2 L at a time until all fluid has been removed. Then add the 2nd 2
L.
b. Perform the flushes in the exact same manner as when flushing out the
acetic acid.
c. Make sure that there is no more fluid in the gas lines before turning the gas
off. It may be best to only turn it off at the end o f the flushes.
9. Add the 2 L of Krebs-Henseleit buffer to the reservoir.
a. Flush each organ bath similar to the previous flushes, except with a smaller
volume.
i. Use approximately 20 mL per organ bath, which is about 3
“volumes”
10. Turn on the gas again and set to the appropriate flow rates.
a. The working pressure should be approximately 15 PSI.
b. Adjusting the individual organ bath, and reservoir gas flow rates is rather
subjective. The guideline is that you want a steady flow o f bubbles, but
without creating a lot o f fizzing/bubbling at the surface
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11. Leave the gas on for about 20 minutes.

Calibration
12. As this is going on, calibrate the transducers
a. If not already done, turn on the computer and PowerLab acquisition
hardware, and log in.
b. Hang each “upper leg” o f the tissue holders on each o f the transducers.
c. Open the LabChart 7 program.
d. Adjust the settings if not already saved
i. Click on the “channel settings” button and a window with settings
opens
ii. Change the number o f active channels to “4” in the box near the
bottom of the window and close the window.
iii. Optional: Change the “sampling frequency” in the top right area of
the window to 100 Hz (default is 1 kHz). There is no noticeable
difference in using frequencies above 100 Hz. Secondly, sampling
at a lower rate reduces computer resource usage (RAM) and makes
files smaller when saved.
iv. Optional: Drag each channel “value display” from the right hand
side onto the main chart area, and resize to make the values clearly
visible from a distance.
v. Press the “Start” button in the lower right side of the window to
start recording, and set the “display scale” (just below the chart
area) to 5:1 or 10:1 (50:1 or 100:1 if using a 1 kHz sampling
frequency).
vi. Tip: If voltages are not close to 0 V, adjust the “zeroing screw” on
the BRAM-4 amplifier with a screwdriver. Turning the screw
clockwise makes the voltage more negative, and counter clockwise
makes it more positive.
vii. If voltages are close to 0 V, then sequentially hang the 10 g weight
on each o f the tissue holder “upper leg” for a few seconds. Be
very careful to ensure the weight is very steady and not swinging
like a pendulum.
viii. Once this is done, press the “Stop” button in the lower right side of
the window to stop recording.
ix. In each o f the channel chart areas, highlight a portion o f the
recording in which the 10 g weight had been hung from the tissue
holder upper leg. Make sure the highlight includes areas with and
without the added 10 g weight.
x. In each o f the channel “side bars” (on the right), the press on the
lower drop-down menu and select “unit conversion”.
xi. A window pops up with several settings and a representation of
your highlighted area.
xii. In the top right of this window select “g” as the unit you want to
convert to from the drop-down box, and set the number o f decimal
places to 3.
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xiii. Just to the left of “unit drop-down box”, set each o f the points to 0
and 10 g.
xiv. In the recording shown at the bottom, select a region that
corresponds to 0 g tension, and press on the “arrow” button to the
left o f the empty box corresponding to the 0 g row. Do the same
for 10 g.
xv. Do this for each of the channels.
13. Once the transducers are calibrated, wipe down all o f the tissue holders (upper
and lower legs) with 70% ethanol.
a. Tip: It’s easiest to just put them all on a Kimwipe and spray them all at
once with ethanol.
14. After about 20 min o f aerating the buffer, collect about 200 mL o f KrebsHenseleit buffer directly from the reservoir.
15. Turn off the gas flow, and quickly release the gas pressure from the oxy-manifold.
16. Place the collected amount o f Krebs-Henseleit buffer in the 4°C refrigerator
immediately, and make sure to seal the container tightly.

Dissection
17. Prepare the dissection area and tools needed.
a. Either use a large tray with its surface covered in paper towels, or a piece
of “LABMAT” plastic cover on the bench as a dissection surface.
b. Find a large container to fill with ice.
i. Both the previously collected Krebs-Henseleit buffer as well as
some Petri dishes will be placed on ice.
c. Find the dissection tools: “rat-tooth” tissue forceps, large sharp/blunt end
scissors, medium blunt end scissors, small surgical scissors, 2 fine-tip
curved dissection forceps, and a large haemostat.
d. Set up the dissection “snake-neck” lamp.
e. Set up about 6 - 8 small Petri dishes (without lids).
f. On one Petri dish, tape a small pre-made 2 mm x 2 mm grid so that the grid
can be seen through the bottom of the Petri dish.
g. Find dissection goggles and a fresh pair o f gloves.
h. Find another small container to fill with distilled water. This is just so that
you can leave the dissection tools in water after they are used to prevent
them from drying up.
i. If collecting a piece o f aorta or other tissue for molecular analysis, find a
Dewar vacuum flask and fill it with liquid nitrogen.
18. Weigh the rat to be sacrificed and prepare the sodium pentobarbital injection.
a. In a 1 cc syringe, draw up a volume o f sodium pentobarbital approximately
equivalent to 0.11 mL/100 g body weight.
19. Inject the rat with the drawn up volume o f sodium pentobarbital using the
intraperitoneal route.
a. Leave the rat in a cage without bedding (or some other container) and wait
until the rat becomes limp.
20. Take the rat to the dissection area and lay it down supine.
21. Routinely check the rat for responsiveness to pain.
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a. Pinch its feet and/or its abdominal skin with the large tissue forceps (with
teeth) and watch for muscle twitches (limb movement) in both the upper
and lower limbs, as well as a very quick breath hold followed by a large
gasp. These indicate that the rat is still sensing pain.
b. Once the rat is no longer responding to these stimuli, dissection may begin.
c. Remember to turn on the dissection lamp and focus the light onto the rat.
22. With the large tissue forceps in your left hand grab on to abdominal skin (and
underlying abdominal muscle) at the midline of the body at a level just rostral to
the hips and pull it up away from the underlying tissue. With the large
sharp/blunt end scissors in your right hand, begin to cut through the skin and
muscle being held up by the forceps.
23. Once through this layer, carefully cut (with the same scissors) the skin and muscle
laterally in both directions from the initial incision without damaging the
underlying viscera.
24. Return to the initial incision, and continue cutting (with the same scissors)
rostrally along the midline until you just about reach caudal edge of the sternum
(xyphoid process).
25. As before, cut (with the same scissors) laterally in both directions just rostral to
the rib cage.
26. Fold away the abdominal skin and muscle to fully reveal the abdominal cavity.
27. Push away the liver (push it caudally) to reveal the rhythmically contracting
diaphragm.
28. Pour into two of the Petri dishes a thin layer o f the pre-oxygenated KrebsHenseleit buffer, and reseal the container it is in. You can now leave the KrebsHenseleit buffer at room temperature as you perform the dissection.
29. With the sharp end o f the large sharp/blunt end scissors (the ones you’ve been
using up to this point), poke through the diaphragm.
a. At this point, you must excise the aorta as soon as you can since the body is
now losing oxygen so be quick.
30. Cut (with the same scissors) away the diaphragm by following it’s attachment to
the rib cage and as far dorsally as possible.
a. The less the diaphragm is attached to the dorsal parts o f the rib cage, the
easier it will be to remove the aorta.
31. With the large tissue forceps (with teeth) still in your left hand, grab the rib cage
and lift it up. You should see the beating heart under it. Very carefully, cut (with
the same scissors) away the visible connective tissue connecting the ventral
surface o f the heart to the dorsal surface of the rib cage.
32. Carefully cut through the rib cage on two lines in a rostral direction (starting
lateral to the midline on both sides, and caudal to the arm pits).
33. Carefully lift away the sternum and part of the rib cage you’ve cut, and cut away
the remaining connective tissue connecting the heart to the stemum/rib cage.
34. Grab this “lifted” part o f the rib cage with the large haemostat and lock it in place.
Open up the thoracic cavity (similarly to opening the hood of a car).
35. With one o f the fine-tip curved dissection forceps in your left hand, grab the
thymus gland which is ventral and slightly rostral to the heart, and cut it away
with the medium blunt end scissors in your right hand.
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36. Try to find the origin o f the aorta on the rostral edge o f the heart (it looks white
compared to the rest of the heart).
37. Grab the aorta at the base with the fine-tip curved dissection forceps and attempt
to lift the heart up
38. Cut out the heart with the same scissors (be careful not to damage any more of the
aorta), and quickly place Kimwipes into the thoracic cavity (there will be a lot of
blood).
39. Quickly soak up and wipe out most of the blood in the thoracic cavity with
Kimwipes.
40. Using the same forceps and scissors, grab the amorphous connective tissue just
caudal of the neck (as far rostral as possible), and cut through dorsally to the
vertebral column.
41. Pull the connective tissue away from the vertebral column as you cut away its
connections to it.
42. Continue to very carefully cut along the vertebral column (in a caudal direction).
You should begin to see tributary arteries coming off o f the vertebral column, and
possibly even the aorta itself.
a. As you continue cutting, try to minimize stretching the tissue (and aorta) as
it may introduce extra cellular stress)
43. Continue cutting away the tissue from the vertebral column until you’re reaching
past the diaphragm. Cut any remaining piece o f the diaphragm, and finally make
a transverse cut to completely excise the tissue.
44. Immediately place the excised tissue in one o f the Petri dishes with KrebsHenseleit buffer in it.
45. Turn the tissue so that it is resting on its ventral surface. On the exposed dorsal
surface, the aorta should now be visible.
46. Grab the aorta with the same forceps from its abdominal (caudal) end and lift it
away from the rest of the tissue. With the same scissors, very carefully cut away
the aorta (towards the arch, rostral direction) from the rest o f the tissue, and place
it in a new Petri dish with Krebs-Henseleit buffer.

Ring preparation
47. Carefully, but quickly, clean the aorta o f all connective and adipose tissue.
a. If the arch of the aorta will not be used for any subsequent molecular
analysis, then there is no need to clean this portion o f the aorta.
b. There are two techniques that are used in combination to quickly clean the
aorta:
i. First, using the two fine-tip dissection forceps grab pieces of
connective tissue and gently pull the connective tissue apart (i.e.
make it less dense).
ii. NB: Take great care not to directly handle the aorta, or when
pulling the connective tissue apart, to not stretch (in any direction)
or twist the aorta.
iii. Second, once the connective tissue has been pulled a sufficient
distance away from the aorta (essentially, once you can see the
surface o f the aorta under the connective tissue), use one set of
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fine-tip forceps to lift it away from the aorta, and the small surgical
scissors to cut it away.
iv. Continue using these two techniques to completely clean the aorta.
v. Tip: Begin with the posterior surface of the aorta at its abdominal
(caudal) end.
vi. Tip: If done properly, connective tissue can be cut away from the
aorta in large continuous portions.
vii. Tip: pulling away the connective tissue, as described above, can
also remove some connective tissue (also in large portions in done
correctly).
viii. Tip: If pressed for time, only clean the sections o f the aorta that
will be needed for analysis.
c. During dissection, place the aorta in fresh Krebs-Henseleit buffer every 5
minutes.
48. When finished cleaning, place the aorta into the dish with attached 2 mm x 2 mm
grid.
49. Using a new razor blade, and if not already done so, cut off the arch o f the aorta
just distal to the beginning o f the thoracic aorta.
50. Line up the aorta using the grid, and using the razor blade, cut several (up to 4) 2
mm-long tubes/rings.
a. If blood clots remain in the lumen of the aortic rings, very carefully attempt
to remove them.
i. First, grab the ring if possible with forceps and shake it.
ii. If the blood clots remain, use the fine-tip forceps to reach into the
lumen to grab them
iii. NB: only reach into the lumen if the blood clot is big enough to
grab, and do so only once. The more times that it is attempted, the
greater the risk of damaging the endothelium.
51. If the rest of the aorta (including the arch) is to be used for biochemical analysis,
cut up the aorta into several other short tubes of arbitrary length.
a. Also attempt to remove the blood clots from these sections being equally as
careful.
52. Place these pieces o f aorta into a 1.5 mL Eppendorf tube and flash-freeze in liquid
nitrogen.

Mounting
53. Take the rings (for myography) to the myograph system along with a pair o f finetip forceps.
54. Turn on the gas once again, and make sure any residual Krebs-Henseleit buffer is
pushed out o f the gas lines.
55. Empty each organ bath and refill with fresh Krebs-Henseleit buffer.
a. Make sure the fresh buffer is warm (i.e. not at room temperature).
i. To do this, allow buffer to flow through the organ bath. As it
flows through, place your finger where the buffer is flowing out to
feel its temperature.

>

56. Very
a.

b.
c.
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ii. NB: this is not an accurate measurement of temperature, but it is
possible to sense the difference between 37°C buffer and room
temperature buffer.
iii. When warm buffer starts to flow out of the organ bath, close the
outflow clamp to fill up the organ bath.
carefully, but quickly, mount each aortic ring onto the myograph system.
Set up the lower leg o f the myograph unit (a single set o f upper and lower
legs).
i. Tip: Set up only one lower leg at a time.
Start recording on LabChart (press “Start” in the lower right comer of the
window).
There are two techniques for mounting rings:
1)
i. Place the upper leg o f the myograph unit onto the force transducer.
ii. Align the upper and lower legs (using the micrometers) so that the
two tissue holder needles are touching. The upper leg needle may
rest on the lower leg needle.
iii. Pick up a ring by putting the needle of a second upper leg through
the lumen. Again be very careful to not excessively touch the
endothelium (the needle should only touch the endothelium where
it is being lifted from). An illustration o f this can be seen in Figure
A below.
iv. Using this second upper leg, place the ring onto the myograph unit
by sliding the already-set upper and lower legs into the lumen as
well. At this point, three needles will be inside the lumen o f the
ring.
v. Carefully, transfer the ring onto the upper and lower leg needles of
the myograph unit, and pull the second upper leg needle out. An
illustration of this process can be seen in Figure B below.

2)
vi. As before, place the upper leg on the myograph and align the two
needles.
vii. Once aligned, remove the upper leg, and manually push the lower
leg back a few mm.
viii. Pick up a ring as before, however this time with the same upper leg
that makes up the myograph unit.
ix. Place the upper leg, with ring, back onto the force transducer.
x. Align the upper and lower leg needles, and “slide” the lower leg
needle into the lumen o f the ring. An illustration o f this process
can be seen in Figure C below.
57. Once mounted, quickly adjust the tension using the vertical micrometer to about
0.7 - 1 g.

90

A

C

Equilibration
58. Quickly and very carefully lower the myograph unit into the organ bath.
a. Lower the unit until the ring is at about the center of the organ bath.
b. Once in the buffer, readjust the tension to approximately 1 g.
59. Continue mounting the remaining aortic rings and adjust tensions to 1 g.
60. Allow the rings to remain at this length/diameter for 5 minutes (the time begins
when the last ring has been lowered into the organ bath)
a. Tip: Although the tension was set at initially at 1 g, this tension gradually
decreases as the rings relax. Tensions may drop down as low as 0.4 g by 5
minutes.
61. At 5 minutes, readjust tension to 1.5 g, and then to 2 g at 10 minutes.
62. After setting tension to 2 g, replace the buffer with fresh Krebs-Henseleit buffer.
a. As before, make sure the buffer is warm and not at room temperature. This
should always be ensured when changing buffers (also called herein
“washing”).
63. Allow the rings to remain at this length/diameter for 60 minutes.
a. Wash/change buffer at 30 and 60 minutes.
b. As before, the tension gradually decreases as the rings relax. Tensions
typically decrease to about 1.7 g.
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c. Tip: the length o f this equilibration period may be altered. For instance, 30
minutes or less may be used instead o f 60 minutes.
64. During this 60 minute equilibration period, prepare PE and ACh dilution series in
1.5 mL Eppendorf tubes.
a. PE needs to be made fresh. Measure out 0.041 ± 0.001 g o f PE and place
into a 15 mL Falcon tube.
b. Dissolve the PE in Krebs-Henseleit buffer (e.g. buffer left over from
dissection) and top up to approximately 2 mL. This creates a 0.1 M (i.e. -1
log M) PE solution.
c. Create several PE and ACh dilution series tubes:
i. PE (in log M): -2, -3, -3.5
ii. ACh (in log M): -2, -3, -3.5, -4, -4.5, -5
d. For ten-fold dilutions (e.g. -1 to -2 log M), pipet 100 pL of solution (e.g. -1
log M) into 900 pL o f Krebs-Henseleit buffer.
e. For approximately three-fold dilutions (e.g. -3 to -3.5 log M), pipet 300 pL
o f solution (e.g. -3 log M) into 700 pL o f Krebs-Henseleit buffer.
i. NB: This dilution makes concentrations approximately -3.5 log M.
The actual concentration is -3.5229 log M.

Viability test
65. Once equilibration is complete, and after the 60 minute wash/buffer change, pipet
5 pL o f -3.5 log M PE into each organ bath.
a. After the last wash, make sure each organ bath has approximately 5 mL of
buffer in it.
b. The final concentration o f PE in the organ bath is -6.5 log M.
c. Tip: Make sure to add comments in the upper section o f the chart view
each time a new pharmacological agent is added or a wash is performed.
66. Wait for the tension to reach a new plateau.
a. Tip: tension should begin to increase within 10 seconds after the addition
of PE.
b. Tip: tension increases in an exponential fashion and should plateau at about
3.5 - 4 g in approximately 1 5 - 2 0 minutes.
67. Once plateau is reached, pipet 5 pL o f -3.5 log M ACh into each organ bath.
a. The final concentration o f ACh in the organ bath is -6.5 log M.
68. Again, wait for tension to reach a new plateau.
a. Tip: tension should begin to decrease within 10 seconds after the addition
o f ACh.
b. Tip: tension decreases exponentially and should plateau at about 1.7 - 2.5 g
in approximately 5 - 1 0 minutes.
69. Once plateau is reached, begin a series o f 4 washes/buffer changes at 5 minute
intervals.
a. Tip: By the end of these washes (i.e. 15 minutes), tension should return to
baseline levels (i.e. approximately 1.7 g)
b. Tip: the number o f washes used can be less than 4. However, it should be
noted that it is difficult to know whether ACh has been fully washed away.
70. Optional: Allow rings to equilibrate once again for 30 minutes, and wash/change
buffer at the very end.
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Concentration-response experiments
71. At the end o f this equilibration period, and after the wash, pipet 5pL of -3.5 M PE
into each organ bath as before, and follow the same guidelines as before.
a. Tip: PE sometimes causes a greater contraction response after this second
exposure to the same concentration.
72. As tension is increasing in response to PE exposure, prepare an aliquot of insulin
(Novolin ge NPH) in a 1.5 mL Eppendorf tube.
a. Using 1 mL BD syringe, draw out approximately 0.7 mL from the insulin
vial and transfer to the Eppendorf tube.
b. Tip: 0.7 mL is needed for running concentration-response experiments in
two organ baths.
73. Once plateau is reached, begin concentration-response experiments with insulin
and ACh.
a. For insulin, the concentrations (IU/mL) used are: 0.3, 0.75,1.5,2.25, 3,
4.5, and 6.
b. For ACh, the concentrations (-log M) used are: -8, -7.5, -7, -6.5, and -6,
approximately.
74. Insulin concentration response experiment:
a. The concentrations and the volume required at each concentration are given
in the table below.
Insulin
concentration
(IU/mL)

0.3

0.75

1.5

2.25

3

4.5

6

Volume to
pipet (pL)

15

22.5

37.5

37.5

37.5

75

75

A new plateau must be achieved at each concentration before the next
volume is added for the next highest concentration.
c. Tip: plateau is typically achieved between 5-10 minutes.
75. ACh concentration-response experiment:
a. Pipet 5 pL from each corresponding tube into each organ bath. (e.g. for -8
log M, pipet 5 pL from the -5 log M tube; for -7.5, pipet from the -4.5 tube,
and so on).
b. As for insulin, a new plateau must be achieved before the addition of more
ACh at each consecutive concentration.
c. Tip: plateau is typically achieved between 5-10 minutes.
76. NB: After the addition o f ACh or insulin, tension may decrease to a local
minimum (nadir), but then may subsequently increase to plateau at a higher
tension. In this case, either add the next volume of insulin or ACh before the
increase (i.e. at the end o f the nadir) or wait until the plateau. Most importantly,
the addition o f ACh or insulin must be done in a consistent manner, whether at the
nadir or the plateau.

Clean-up
77. Once finished, turn off the gas flow and water pump, raise myograph units and
remove each ring.
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78. If collecting rings for further biochemical analysis, very carefully remove the
rings from the myograph units and place into 1.5 mL Eppendorf tubes.
a. Flash-freeze in liquid nitrogen.
79. If collecting myography buffer for further biochemical analysis, drain buffer into
5 mL plastic culture tubes, and flash-freeze in liquid nitrogen.
80. Flush out any remaining Krebs-Henseleit buffer in the same manner as flushing
out acetic acid at the beginning of the experiment.
81. Pour two litres o f near-boiling ddFLO into the myograph system and allow the
water to flow into the organ baths
a. NB: Always be very careful when pouring boiling water.
b. Optional: Allow the water to sit in the myograph system for about 10
minutes.
82. Flush out the water in the same manner as when performing washes at the
beginning o f the experiment.
83. Optional: Perform a second flush as before with near-boiling ddf^O .
84. Optional: Pour 2 L of 10% acetic acid into the myograph system and allow the
water to flow into the organ baths.
a. Leave the acetic acid in the myography system overnight.
b. NB: Make sure to clean out the acetic acid the following day even if
experiments are not being run.
c. Tip: this method of cleaning is not highly recommended as prolonged use
may lead to deterioration o f metallic components.
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A2. Co-Immunoprecipitation protocol
Proteins tested:
IP: eNOS - WB: Hsp90

Tissues tested:
Aorta

Before you begin
Make sure you have the following solutions:
Homogenizing/IP buffer12(25 mM Tris, 150 mM NaCl, pH 7.2)
2X Laemmli buffer2 (4%SDS, 20% Glycerol, 10% p-mercaptoethanol, 0.015%
bromophenol blue, 0.125 M Tris pH 6.8)

Homogenization
NB: If using previously frozen homogenates, skip ahead to the “Set-up” sub-section.
However, due to the sensitivity o f protein-protein interactions it may be necessary to
perform CoIP on freshly-homogenized tissue. Therefore, the protocol for
homogenization, for CoIP purposes, is outlined here.
NB: Again, due to the sensitivity of the protein-protein interactions two general technique
pointers are recommended:
1) Always keep samples on ice or in 4°C environments throughout the CoIP
protocol. Samples may only be left at room temperature or higher at the end
o f the protocol (which will be made evident below)
2) Avoid vortexing o f samples throughout the CoIP protocol. Again, samples
may only be vortexed at the end o f the protocol. To mix samples, invert tubes
several times and flick tubes with your fingers.
1. Take samples from the -70°C freezer and place in < -30°C environment (e.g.
cryostat)
a. NB: Do not let tissues thaw.
b. Tip: Each sample will require 1.4 - 2.8 mL o f homogenizing/IP buffer1 so
calculate how much will be required for a single CoIP experiment
beforehand and place in 15 mL Falcon tubes.
c. Tip: Keep homogenizing/IP buffer1 on ice at all times.
d. Tip: Calculate the approximate amount of homogenizing/IP buffer will be
needed for a single run-through o f CoIP.
i. Each sample will need no more than 1400 pL (2800 pL if run in
duplicate) if CoIP is performed as outlined here.
ii. NB: Aliquot this amount and add the following protease and
phosphatase inhibitors to this aliquot. Do not add the inhibitors to
the stock solution.
1. protease inhibitors (1:100; Sigma # P8340)
2. serine/threonine phosphatase inhibitors ( 1:100; Sigma #
P2850)
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3. tyrosine phosphatase inhibitors (1:100; Sigma P5726).
e. Tip: Prepare several sets of 1.5 mL Eppendorf tubes for the following
purposes as follows and keep on ice at all times:
i. HomogenatesA
ii. Centrifugation supernatants8
iii. IP reaction0
iv. IP supernatants0 (optional)
2. Cut frozen tissues using a razor blade into sections to be weighed.
3. Very quickly, weigh out between 0.140 - 0.150 g of tissue, and return to cryostat.
4. Transfer selected tissue into a 2 mL glass-glass homogenizer (a.k.a. Dounce
homogenizer).
5. Pipet 700 - 750 pL o f homogenizing/IP buffer1 into the glass-glass homogenizer.
a. The actual amount pipeted depends on the weight o f tissue cut. Tissue
should be homogenized in a 1:5 weight:volume ratio.
6. Keeping the glass-glass homogenizer in the cryostat, homogenize the tissue.
a. Use consistent and rhythmic pestle strokes (including twisting)
b. Homogenization may take up to 4 minutes and the longer it is done the
more thorough the homogenization. It is recommended to keep the time
o f homogenization consistent.
c. Tip: Some bit o f tissue may not fully homogenize. This is mostly
connective tissue and thus should not be o f concern for these purposes.
7. Decant the homogenate into a “homogenates” Eppendorf tubeA and place on ice.
8. If multiple samples are being run, clean out the glass-glass homogenizer with
dH 2Û and dish soap.
a. Make sure to dry the inside o f the homogenizer before the next use as any
water left may dilute the homogenate further.
9. Continue this same process o f homogenization for the remaining samples.
10. Optional: Once the last sample has been homogenized, leave all samples on ice
for approximately 20 minutes.
a. This is only done to ensure that as much protein as possible is extracted
from the tissue. However, this may not be necessary and should be
empirically tested.
11. Cool the Eppendorf 5804 R centrifuge to 4°C using the “Fast Cool” program.
12. Quickly transfer microcentrifuge tubes into the centrifuge and spin samples at
3000 rpm for 20 minutes at 4°C.
13. Transfer the supernatant to the “centrifugation supernatant” tube8, and place back
on ice.

Set-up
14. Measure protein concentrations in homogenates using the Bradford protein assay.
a. The Bradford assay will not be detailed here
15. Once protein concentrations are known, transfer the same amount of protein from
each homogenate into the new “IP reaction” tubes0.
a. For the CoIP o f eNOS and Hsp90, transfer volumes containing 300 pg of
protein from each homogenate
b. Make sure that samples are kept on ice at all times for the remainder of the
protocol unless otherwise stated.
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c. The remainder of the homogenate can be stored at -70°C if not being used
for other purposes.
16. Equalize protein concentrations across all samples to be analyzed by topping up
the volume to 450 pL.
a. Calculate the correct volume homogenizing/IP buffer1 to add to each
homogenate to do this.
b. This step adjusts protein concentrations to 300 pg/450 pL, or
approximately 0.67 pg/pL, in all samples.
c. Tip: This step is performed so that the amount of antibody used per
sample is the same for all samples in both per pg o f protein and per pL of
solution bases.

Immunoprecipitation
17. Pipet 30 pL o f IP antibody into each sample (i.e. into each IP reaction tubec).
a. Antibody: Santa Cruz sc-654 AC rabbit pAb anti-eNOS agarose conjugate
b. Concentration: 15 pg/480pL, or 0.031 pg/pL
c. Dilution: 30 pL:450 pL, or 1:15
d. NB: Agarose-conjugated antibodies exist as beads which easily
precipitate. Therefore, each time antibodies are pipeted from the vial,
gently vortex the vial to resuspend the agarose beads.
i. Once antibody has been pipeted into the IP reaction tube0,
confirmation of the adequate transfer of agarose beads can be
made. Invert and flick the tube several times. Agarose beads stick
to the edges o f the tube and are easily visible.
18. Allow samples and antibody to incubate overnight ( 1 8 - 2 2 hours) at 4°C
(refrigerator) on a “rotisserie-style” shaker.
a. To fasten tubes to the shaker, place up to 6 IP reaction tubes0 in a single
50 mL Falcon tube and tape the Falcon tube to the shaker.
19. Before antibody incubation is stopped, cool the Eppendorf 5804 R centrifuge to
4°C using the “Fast Cool” program.
20. Quickly transfer IP reaction tubes0 into the centrifuge and spin samples at 14000
RCF (a.k.a. g) for 20 minutes at 4°C.
a. Once centrifugation is complete, do not turn off the centrifuge as it will be
used again. Secondly, the centrifuge can serve as a 4°C refrigerator while
the following steps are being performed.
21. Remove the supernatant from each tube.
a. At this point, eNOS should be found attached to antibody, which is
attached to the agarose beads. In other words, eNOS should not be found
in the supernatant.
b. If the supernatant is to be collected for further analysis, transfer the
supernatants to the new “IP supernatants” tubeD.
c. The approximate volume of supernatant will be 450 pL. This, however,
depends on the volume used per sample as described above.
d. Tip: Hold the Eppendorf tube up against a source of backlighting to more
easily see the pellet.
e. NB: Be very careful not to disturb or pipet the agarose pellet.
i. Do not invert, shake, flick, etc the tubes.
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ii. When pipeting the supernatant, pipet slowly so as to not create
fluid flow that may disturb the pellet

Washing
22. Pipet 150 pL o f homogenizing/IP buffer1 into each IP reaction tubeA (now
containing only the agarose pellet) and mix the contents once again as
recommended above.
a. Tip: Do not let the agarose pellet dry up. Work with only a single IP
reaction tubeA for steps 21 and 22. As soon as the homogenizing/IP
buffer1 has been added and the contents mixed place the tube on ice or
back in the centrifuge.
23. Transfer tubes back into the Eppendorf 5804 R centrifuge and spin samples at
14000 RCF for 5 minutes at 4°C.
24. Remove the supernatant from each tube following the same recommendations as
before.
a. This supernatant can normally be discarded. However, it may also be o f
interest to collect and analyze these supernatants for the loss o f eNOS or
its binding partners during washing.
25. Optional: Repeat steps 22 to 24 several times.
a. This may be necessary if too much “background” binding to eNOS or the
agarose beads occurs.

Elution
26. Pipet 50 pL o f homogenizing/IP buffer1 into each IP reaction tubeA (again
containing only the agarose pellet).
a. Tip: Again, do not let the pellets dry up.
27. Pipet 50 pL o f 2X Laemmli buffer2 into each IP reaction tubeA.
a. Tip: Different amounts o f homogenizing/IP buffer1 and 2X Laemmli
buffer2 may be added but make sure equal amounts of each are used (i.e.
ensure a 1:1 ratio between them exists)
b. From this point onwards, samples may be left at room temperature and
may be vortexed.
28. Thoroughly mix samples by vortexing.
29. Bring water in a metal container to near-boiling temperature, and place samples in
water.
a. Leave samples in hot water for 10 min.
b. Tip: boiling may cause tube caps to pop, which presents the risk of either
losing the sample or having water spill into the tubes. Thus, it is
recommended that water be heated to near-boiling temperatures, but not
quite cross that threshold.
30. Remove the tubes from hot water and let cool at room temperature.
31. Transfer tubes to an Eppendorf centrifuge (either 5804 R or 5415 C) and spin
samples at 10000 rpm for 10 minutes at room temperature.
32. Remove the supernatant from each tube.
a. At this point, eNOS should be denatured and not attached to the antibody
or agarose beads. In other words, eNOS should be found in the
supernatant.
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b. Transfer the supernatants to a new Eppendorf tube and store at 4°C
(refrigerator). Make sure to run western blots on these samples within a
week o f CoIP.
c. Tip: Hold the Eppendorf tube up against a source o f backlighting to more
easily see the pellet. This is especially important here since Laemmli
buffer2 is quite opaque.
d. Tip: Be careful not to disturb or pipet the agarose pellet.
i. Do not invert, shake, flick, etc the tubes.
ii. When pipeting the supernatant, pipet slowly so as to not create
fluid flow that may disturb the pellet
iii. This is important so that the supernatant is not contaminated with
agarose beads. Contamination may make gel loading (described in
the “Western Blotting Protocol” section) inconsistent which may
alter results.
33. Remaining agarose beads may be discarded.

Solutions
Name
1.

Homogenizing/IP
buffer

2.

2X Laemmli buffer

Components,
concentrations, pH
Tris - 0.025 M
NaCl - 0.15 M
p H - 7 .2
T r i s - 0.125 M
Glycerol - 20% (v/v)
S D S -4 %
p -mercaptoethanol 10% (v/v)
Bromophenol blue 0.015% (w/v)
pH - 6.8

Example amounts

Storage

T r is - 1.51 g
N a C l - 4.38 g
Total V - 500 mL
Tris - 7.57 g
Glycerol - 1 0 0 mL
SDS - 20 g
P -mercaptoethanol
- 50 mL
Bromophenol blue 0.075 g
Total V - 500 mL

4°C

Room
temperature,
fumehood
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A3. Western Blot protocol
Proteins tested:
eNOS, Hsp90, Hsp70, phosphoSl 177-eNOS, phosphoT495-eNOS

Tissues tested:
Heart, Soleus, Lung, Aorta, Red Gastrocnemius

Before you begin
Make sure you have the following stock solutions:
10X Tris buffered saline (TBS; 100 mM Tris pH 7.5,1 M NaCl)
10X Running buffer (250 mM Tris (don’t adjust pH), 1.92 M Glycine, 1% SDS)
Acrylamide solution1(30% acrylamide, 0.8% bis-acrylamide)
Separating gel buffer2 (1.5 M Tris pH 8.8,0.4% SDS)
Stacking gel buffer5 (0.5 M Tris pH 6.8, 0.4% SDS)
Sodium dodecyl sulphate (SDS) solution3 (10% SDS)
2X Laemmli SDS-PAGE sample buffer 4 (4% SDS, 20% Glycerol, 10% pmercaptoethanol, 0.015% bromophenol blue, 0.125 M Tris pH 6.8)
Water-saturated butanol

Separating gel
1.
2.
3.
4.

Take samples, positive controls, “ladders”, etc and allow them to thaw on ice.
Clean mini-gel plates with 70% ethanol before use.
Assemble gel cassettes, and look for leaks with water if desired.
Prepare separating gel in a small beaker with continuous stirring.
a. A 6% gel is best for eNOS, but 7.5% works also; the volumesA here are for
four 1.5 mm thick 6% polyacrylamide gels.
b. Prepare a 10% ammonium persulfate (APS) solution; it is important to
prepare this fresh every time. Measure out 50 mg of APS powder, place
into a 1.5 mL Eppendorf tube, and add 450 pL o f double distilled water
(ddH20 ).
c. Add 21.4 mL of ddH20 .
d. Add 8 mL o f Acrylamide solution1; begin to stir.
e. Add 10 mL o f Separating gel buffer2.
f. Add 400 pL sodium 10% SDS3.
g. Let stir for a minimum o f 10 min.
h. Add 250 pL of 10% APS solution and 25 pL of
tetramethylethylenediamine (TEMED) simultaneously and let stir for about
20 seconds.
5. Quickly pour the gel into each cassette with a Pasteur pipet up to about 1.5 cm
from the top of the “short” plate.
6. Try to remove most bubbles by tipping apparatus and/or soaking them up with
filter paper.
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7. Immediately, but very carefully and gently, overlay each gel with about 1 cm o f
water-saturated butanol.
8. Allow gel to polymerize for 30 - 60 min (longer is better).
a. Tip: keep some of the gel in the Pasteur pipet. This will tell you if the gel
is successfully polymerizing.
b. Tip: Do not touch the apparatus as the gel is polymerizing to ensure that it
polymerizes evenly.
9. While this is taking place, continue preparing your samples:
a. There are two methods to preparing, and subsequently loading, samples. In
both methods, equal amounts of total protein from each sample will be
loaded. The difference is whether equal volumes, and thus equal protein
concentrations, will be loaded.
b. Method 1:
i. Once thawed, mix samples (eg. by vortexing), and pipet
appropriate volumes into a second set o f labelled tubes.
ii. Add an equal volume o f 2X Laemmli SDS-PAGE sample buffer 4
to each tube
iii. Each tube should now be a 1:1 mixture o f homogenized sample to
the sample buffer.
c. Method 2:
i. Exactly as method 1, mix samples and pipet appropriate volumes
into a second set o f labelled tubes.
ii. However, equalize volumes across the samples by topping up with
homogenizing buffer.
iii. Then add a volume of 2X Laemmli SDS-PAGE sample buffer 4
equal to the new total volume in each tube.
iv. As above, each tube should now be a 1:1 mixture of homogenized
sample to the sample buffer.
v. All tubes should also have the exact same volume and
consequently, the same protein concentration.
d. Mix samples thoroughly, and centrifuge to pull all contents down if
necessary.

Stacking gel
10. Clean lane combs with 70% ethanol.
11. Prepare the 4% stacking gel in a small beaker with continuous stirring.
a. The volumes8 here are for four 1.5 mm thick 4% polyacrylamide gels.
b. Add 12.2 mL o f ddH20 .
c. Add 2.6 mL of Acrylamide solution1; begin to stir.
d. Add 5 mL o f Stacking gel buffer5.
e. Add 200 pL 10% SDS3.
f. Let stir for a minimum o f 10 min
12. While this is stirring, and separating gel has polymerized, dump the butanol
overlay down the sink and rinse with ddH 20.
13. Dry the exposed glass plates (above separating gel) with filter paper.
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14. To the partially complete gel, and after 10 min o f stirring, add 125 pL o f 10%
APS solution (same as previously used) and 25 pL of TEMED simultaneously
and let stir for about 20 seconds.
15. Quickly pour the gel into each cassette with a Pasteur pipet up to the top of the
“short” plate.
16. Carefully place lane combs in between the two plates, making sure no bubbles are
trapped beneath it.
a. Tip: slide comb in at an angle.
17. Allow gel to polymerize for 30 - 60 min (longer is better).
a. Tip: keep some o f the gel in the Pasteur pipet. This will tell you if the gel
is successfully polymerizing.
18. While this is taking place, continue preparing your samples:
a. Bring water in a metal container to about 75 - 80°C, and place samples in
water; maintain this temperature range.
i. Leave samples in hot water for 10 min.
b. Remove from hot water and let cool at room temperature before loading
onto gel.
c. Mix samples again by vortexing, and centrifuge to pull down contents if
necessary.
d. Prepare IX running buffer6 (25 mM Tris, 192 mM glycine, 0.1 % SDS)
from 10X running buffer if not done so previously, and place in
refrigerator. About 1 L is needed per electrophoresis unit.

Gel Loading
19. Once stacking gel has polymerized, carefully remove gel cassettes from apparatus
and transfer to the electrophoresis electrode modules.
a. Each BioRad Mini-Gel Protean Tetra Cell electrophoresis unit holds one
“electrode” module and one “companion” module, and each module holds
two gels. If running only two gels, you must use the “electrode” module.
b. Make sure each cassette is as far down as possible on the modules.
c. Make sure the “short” plate faces the inside o f the module.
d. For electrophoresis to work, you need a closed-in compartment on the
inside. If running an odd number o f gels, you can place an unused cassette,
but with the “spacer” plate facing the inside, opposite to the lone gel in
order to seal off the inside compartment.
e. Tip: at this point, be sure you can identify your gels.
20. Very carefully remove the lane combs from gel, and fill each well about halfway
with IX running buffer6 with a Pasteur pipet.
21. Load the correct amount of each sample into the corresponding wells using a
micropipet (2 - 20 pL or 10 - 100 pL) with loading tips.
a. If samples were prepared via Method 1 as described above, then each well
will contain different volumes o f sample to equalize protein amounts.
b. If samples were prepared via Method 2 as described above, then each well
will contain the same volume o f sample as protein concentrations are all
the same.
c. If using the BioRad chemiluminescent molecular weight marker (“ladder”;
Precision Plus Protein WestemC Standards #161-0376):
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i. Load 3 pL for a 1.5 mm thick gel using the 10-lane comb.
ii. Load 2.5 pL for a 1.5 mm thick gel using the 15-lane comb.
d. If not using a chemiluminescent ladder (BioRad Precision Plus Protein
Standards Kaleidoscope #161-0375 or #161-0324):
i. Load 5 pL for a 1.5 mm thick gel using either the 10-lane or 15lane combs.
22. Fill each well up to the top with IX running buffer6 using a Pasteur pipet.
23. Fill the inside compartment o f the electrode modules with cold IX running buffer6
to a level above the short plate; this covers the wells.
a. Tip: if the volume o f the inside compartment drops as you try to fill it, then
there is a leak.
24. Fill the rest o f the tank (outside the gel cassettes) with cold IX running buffer6 to
the same level.
25. Optional: remove all bubbles from under the gel cassettes with a syringe pipet.

Electrophoresis
26. Place electrophoresis unit into a second larger container, and cover it with the lid.
a. At this point, ensure that electrodes match on the modules and the lid; i.e.
positive with positive, negative with negative, or red with red, black with
black
27. Fill the container with ice.
28. Connect the lid electrodes to the power unit (again red with red, black with black),
set voltage to 150, and press the “run” button.
a. Tip: Higher voltages create more heat which can cause lanes to curve, so
keeping the running buffer6 cold ensures that the lanes remain straight.
29. Allow electrophoresis to occur until the bromophenol blue dye front rims
completely through the gel.
a. It takes about 2 hours with a 6% gel.
30. As this is taking place, and if not done so previously, make transfer buffer7 (25
mM Tris, 192 mM glycine, 0.1 % SDS, 20% methanol), and cut filter paper and
nitrocellulose.
a. About 1 L o f transfer buffer7 is needed per transfer unit.
b. Cut out 14 pieces o f filter paper per transfer unit (7 per “sandwich”) to 7
cm x 10 cm size.
c. Cut out one piece o f nitrocellulose per gel to a 6.5 cm x 9 cm size. Be sure
to somehow mark each piece of nitrocellulose to identify the different
blots.
31. Put a layer (arbitrary volume) o f cold transfer buffer7 into two separate baking
dishes.
32. In one dish, soak the nitrocellulose pieces, and in the other soak the filter paper
and Brillo pads.
a. Soak for about 20 min.
b. Aside: This step and length of time is even more important, if not critical,
when using PVDF instead of nitrocellulose.

Transfer
33. Once electrophoresis is complete, and after 20 min o f soaking nitrocellulose,
unplug electrophoresis unit, and remove the lid.
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34. Very carefully, remove the gels from the electrode modules one at a time.
a. Using the “wedge” piece, separate the short and spacer plates to reveal the
gel itself.
b. With a clean razor, slice off the stacking gel.
c. With the same razor, make small cuts to identify the “top” of the gel, as
well as make markings that match the corresponding pieces of
nitrocellulose.
35. Place gels into transfer buffer7 in the same baking dish containing the
nitrocellulose pieces.
a. Immerse the spacer plate (with gel still adhering to it) into the transfer
buffer7 in the baking dish with the nitrocellulose pieces.
b. Using the “wedge” piece, very carefully dislodge each gel from the spacer
plate.
36. Assemble the transfer apparatus (“sandwich”) in the baking dish with the filter
paper, and Brillo pads.
a. Place the “positive” end (white) of the sandwich frame on the bottom.
b. Stack the individual components as follows: 1 Brillo pad, 2 filter papers, 1
nitrocellulose piece, corresponding gel, 3 filter papers, 1 nitrocellulose
piece, corresponding gel, 2 filter papers, 1 Brillo pad. The “negative” end
(black) of the sandwich frame is on top, and secures the sandwich. This
can be visualized in the figure below.

2 gels

1 gel

4

(

Ml

1

Negative frame
Positive frame
B rio pad
Fiter paper
Nirocelkibse

Gd

c. Because the gel is very adhesive to the nitrocellulose in air, it is
recommended to match each piece o f nitrocellulose to the corresponding
gel while submerged in transfer buffer7, and then moving them over
together to the other dish where sandwich assembly is occurring.
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37.
38.

39.

40.
41.

42.
43.

d. Make sure that the orientation o f the gels matches the corresponding pieces
o f nitrocellulose. This is far easier to do if you’ve loaded a pre-stained
molecular weight marker.
e. Apply pressure on the sandwich before closing to try to remove bubbles
between the gel and nitrocellulose.
Place the closed sandwich in the transfer electrode module, and place this in the
transfer tank.
Place an “ice pack” in the tank, and fill the tank with cold transfer buffer7.
a. It is okay to use the same transfer buffer7that was in each baking dish.
b. Any portion o f the gel/nitrocellulose not submerged in transfer buffer7 will
not transfer.
Place transfer unit into a second larger container, and cover the unit with the lid.
a. At this point, ensure that electrodes match on the module and the lid; i.e.
positive with positive, negative with negative, or red with red, black with
black
Fill the container with ice.
Connect the lid electrodes to the power unit (again red with red, black with black),
set voltage to 100, and press the “run” button.
a. Tip: The power unit has trouble maintaining higher voltages if the
temperature o f the transfer buffer7 is too high. It is also hard to maintain
higher voltages if there aré more than one transfer units plugged into the
unit at once.
Allow transfer to occur for 70 min.
As this is taking place, and if not done so previously, prepare IX Tween TBS8
(TTBS; 10 mM Tris pH 7.5,100 mM NaCl, 0.1% Tween-20) from 10X TBS, and
blocking solution98, b (5% nonfat, dry milk protein93 (for non-phospho proteins) or
5% BSA9b (for phospho proteins) in TTBS ).
a. Prepare 2 L o f TTBS8 for 4 blots.
b. Select small, shallow containers (small Rubbermaid-like containers work
well) for the rest of the incubations o f the blots.
c. Depending on the size of the containers, prepare 25 - 30 mL o f blocking
solution93, ° per container.

Blocking
44. Once transfer is complete, unplug from the power unit and remove the lid from
the transfer tank.
45. Very carefully remove each piece of nitrocellulose and place in the previously
prepared containers with blocking solution9.
a. Tip: if you use a pre-stained molecular weight marker, you can tell that
transfer was successful if the marker is found on the nitrocellulose and no
longer found on the gel.
b. Tip: Use “flat head” tweezers to handle the nitrocellulose and try to only
handle the nitrocellulose pieces from the edges only.
c. Place only two pieces o f nitrocellulose (from here on referred to as “blots”)
in each container, and make sure they are in a back-to-back orientation.
46. Allow to incubate for 1 hr at room temperature with gentle shaking (~40 rpm).
a. Be sure to cover each container with parafilm, or a lid if available
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47. As this is taking place, prepare the primary antibody solution10,11 (2% nonfat, dry
milk protein10 or 5% BSA11 in TTBS8+ primary antibodies) in 50 mL Falcon
tubes.
a. Make as many tubes as there are containers, and or antibodies.
b. Depending on the size o f the containers, prepare 20 - 25 mL o f antibody
solution10 per Falcon tube.
c. Allow antibody vials to thaw at room temperature, or on ice if being kept
out o f the refrigerator for some time.
d. Pipet into each Falcon tube the appropriate antibody at the correct
concentration
i. BD 610297 mouse mAb anti-eNOS - 1:5000 (use “milk“ primary
antibody solution10)
ii. BD 610418 mouse mAb anti-Hsp90 - 1:2000 (use “milk“ primary
antibody solution10)
iii. StressGen SPA-812 rabbit pAb anti-Hsp70 -1 :1 0 0 0 0 (use “milk“
primary antibody solution10)
iv. CST 9571 rabbit pAB anti-phosphoS 1177-eNOS - 1:2000 (use
“BSA“primary antibody solution11)
v. CST 9574 rabbit pAB anti-phosphoT495-eNOS - 1:2000 (use
“BSA“primary antibody solution11)
48. When blocking is complete, wash blots once with TTBS8.
a. Dump blocking solution9 down the sink and replace with TTBS8 in each
container.
b. Allow to wash for 5 min at room temperature with vigorous shaking (~90
rpm).

Primary Antibody
49. Dump TTBS8 down the sink and replace with the previously prepared antibody
solution10, u .
50. Allow blots to incubate overnight ( 1 2 - 1 6 hours) at 4°C (refrigerator) with gentle
shaking (~60 rpm).
a. Be sure to cover each container with parafilm, or a lid if available.
51. Before primary antibody incubation is stopped, prepare the secondary antibody
solution12 (2% nonfat, dry milk protein in TTBS8 + horseradish peroxidase
(HRP)-conjugated secondary antibodies) in 50 mL Falcon tubes.
a. It is best to use new Falcon tubes every time; however they can be reused if
necessary if washed thoroughly (eg. with soap, bleach, and 70% ethanol).
b. Make as many tubes as there are containers, and or antibodies.
c. Depending on the size o f the containers, prepare 20 - 25 mL o f antibody
solution12 per Falcon tube.
d. Pipet into each Falcon tube the appropriate antibody at the correct
concentration.
i. BioRad #170-6516 goat pAb anti-mouse IgG HRP conjugate 1:5000
ii. BioRad # 170-6515 goat pAb anti-rabbit IgG HRP conjugate 1:10000

106

e. If using the chemiluminescent ladder, and if visualization of it is desired,
also pipet into each Falcon tube the BioRad Precision Protein StrepTactinHRP conjugate (# 161 -03 80) at a 1:15000 dilution.
52. Once primary antibody incubation is done, remove any unbound primary antibody
with three successive washes and rinses in TTBS8.
a. Dump the primary antibody solution10,11 in each container down the sink,
and pour a volume (unspecified) o f TTBS8 into each container.
b. Allow washing to occur for 10 min at room temperature with vigorous
shaking (~90 rpm).
Q
c. Dump out first volume o f TTBS and do a quick rinse o f the blots with new
TTBS8.
d. Dump out the “rinse” TTBS8 and replace with a third volume of TTBS8
(second wash).
e. Repeat this process for a total o f 3 washes.

Secondary Antibody
53. Dump TTBS8 down the sink and replace with the previously prepared secondary
antibody solution12.
54. Allow blots to incubate for 60 min at room temperature with gentle shaking (~40
rpm).
a. Be sure to cover each container with parafilm, or a lid if available.
55. As this is taking place, and if not done so previously, prepare IX Tris buffered
saline13 (TBS; 10 mM Tris pH 7.5, 100 mM NaCl) from 10X TBS.
a. Prepare 100 mL o f TBS13 for 4 blots (2 containers).
56. Once secondary antibody incubation is done, removeoany unbound secondary
antibody with successive washes and rinses in TTBS .
a. Dump the secondary antibody solution12 in each container down the sink,
and pour a volume (unspecified) o f TTBS8 into each container.
b. Allow washing to occur for 10 min at room temperature with vigorous
shaking (~90 rpm).
c. Dump out first volume of TTBS8 and do a quick rinse o f the blots with new
TTBS8.
d. Dump out the “rinse” TTBS8 and replace with a third volume o f TTBS8
(second wash).
e. Repeat this process for a total o f 3 washes.
57. After the last TTBS8 rinse, perform one final rinse with the previously prepared
TBS13 and leave blots in a volume (unspecified) o f TBS13.
a. Be sure to cover each container with parafilm, or a lid if available.
b. Tip: Tape down the parafilm cover (if not using a lid) with masking tape, as
blots will soon be transported.
c. If not imaging right away, place blots in 4°C (refrigerator). Be sure to
image within a few days.

Chemiluminescent imaging
58. Be sure you have the following at the Chemidoc XRS system station:
a. Your blots (in TBS13), “flat head” tweezers, BioRad Immun-Star WestemC
chemiluminescense kit (#170-5070), 1000 pL pipet and tips (at least 3 per
blot), 1.5 mL Eppendorf tubes (at least 1 per blot), overhead transparencies
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(at least 1 per blot), Kimwipes, 70% ethanol, USB key, parafilm, scissors,
masking tape, and gloves.
b. Tip: Cut each transparency in half.
59. Turn on the BioRad Chemidoc XRS System, open the Quantity One 1-D analysis
program, and insert your USB key into the computer.
a. Within Quantity One, select the “band analysis guide” from the toolbar,
and a pop-up with a list o f items should appear on the top right of the
screen.
b. Click on the “select scanner” button, and select the “Chemidoc XRS” from
the subsequent pop-up.
c. A control window should open up. Click on the “Live/Focus” button in
this window, and press the “Epi White” button on the chemidoc system
itself
60. Open up the drawer o f the chemidoc, and clean the inside surface with 70%
ethanol.
61. Prepare the BioRad chemiluminescence substrate in a 1.5 mL Eppendorf tube.
a. Pipet 500 pL o f the Luminol/enhancer solution and 500 pL of the peroxide
solution into the Eppedorf tube, and mix contents well (eg. vortex).
b. 1 mL o f the final solution (500 pL + 500 pL) is plenty for one blot.
62. Remove one o f your blots from the TBS13, drain/shake off some of the TBS13, and
place the blot face up on one transparency (or half of one if you’ve cut it).
63. Pipet onto your blot the chemiluminescence solution, making sure to fully, and
evenly, cover your blot (or at least the area where you expect your bands to show
up).
64. Place a second transparency (or the other half if you’ve cut one) on top of your
blot, and try to press away any bubbles that may have formed between the blot
and transparencies.
65. Place the blot “sandwich” on the chemidoc drawer so that the blot is
approximately in the center, and close the drawer.
66. Open the top door o f the Chemidoc, and align your blot so that’s in the center o f
the camera’s field o f view.
a. First, center your blot manually (reach in and move it).
b. Once centered, zoom in and focus on the blot, using the buttons in the
Quantity One control window.
c. It is best to zoom in as much as possible; your bands should take up the
entire width o f the camera’s field o f view.
67. In the control window in Quantity One, check the “highlight saturated pixels” box
near the bottom, and click on the “Open Iris” button repeatedly.
a. Saturated pixels will be displayed red, and there should be a “pulsating”
ellipse o f red pixels in the center o f the display.
b. Continue pressing this button until the size o f the ellipse is no longer
noticeably increasing.
68. Close the Chemidoc door, and press the “Epi White” button again to turn off the
light.
69. Click on the “Freeze” button in the control window in Quantity One, and then
click on the “Live Acquire” button in the same window.
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a. A pop-up appears, in which you can decide exposure parameters.
b. Choose the total time o f exposure, the time it takes for the first image
capture, and the total number of image captures.
c. Tip: 600 seconds (10 min) total exposure time is adequate.
70. Allow the camera to detect the chemiluminescence for the total exposure time.
a. Out o f the images that are captured as exposure is taking place, select at
least one to analyze.
b. Tip: It is best to choose an image in which your bands of interest are just on
the verge o f saturation.
c. Tip: Hopefully you’ve done the Western Blot with the right conditions in
order to achieve saturation towards the end o f the 10 minutes of exposure;
longer time to saturation is better.
71. Once finished, remove blot from chemidoc, clean the drawer surface with 70%
ethanol again, and repeat the process with the rest o f the blots.

Solutions
Name
1.

Acrylamide
solution

2.

Separating gel
buffer

3.

SDS solution

4.

2X Laemmli
SDS-PAGE
sample buffer

5.

Stacking gel
buffer
10X running
buffer

Components,
concentrations, pH
Acrylamide - 30%
(w/v)
Bis-acrylamide - 0.8%
(w/v)
Tris - 1 .5 M
S D S - 0 .4 % (w/v)
p H - 8 .8
SDS - 1 0 % (w/v)
Tris - 0.125 M
Glycerol - 20% (v/v)
SD S-4 %
p -mercaptoethanol 10% (v/v)
Bromophenol blue 0.015% (w/v)
p H - 6 .8
Tris - 0.5 M
SDS - 0.4% (w/v)
pH - 6.8
Tris - 0.25 M
Glycine - 1.92 M
SDS - 1 % (w/v)

Example amounts

Storage

Acrylamide - 150 g
Bis-acrylamide - 4 g
Total V - 500 mL

4°C

Tris - 90.9 g
SDS - 2 g
Total V- 500 mL
S D S - 10 g
Total V -1 0 0 mL

4°C

Tris - 7.57 g
Glycerol - 1 0 0 mL
SDS - 20 g
P -mercaptoethanol 50 mL
Bromophenol blue 0.075 g
Total V - 500 mL
Tris - 30.3 g
SDS - 2 g
Total V - 500 mL
Tris - 60.6 g
Glycine - 288 g
S D S - 20 g
Total V - 2 L

Room
temperature
Room
temperature,
fumehood

4°C

4°C
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6.

I X running
buffer

10X running buffer 10% (v/v)

7.

IX transfer
buffer

1OX running buffer 10% (v/v)
Methanol - 20% (v/v)

1OX TBS

T ris -0 .1 M
NaCl - 1 M
p H - 7 .5
10X TBS - 10% (v/v)
Tween-20 - 0.1% (v/v)
p H - 7 .5
a. Non-fat, dry milk
protein - 5% (w/v)
b. Bovine serum
albumin - 5% (w/v)
IX T T B S - 95%

8.

IX TTBS

9.

Blocking
solution

10.

Primary
antibody
solution 1

11.

Primary
antibody
solution 2

12.

Secondary
antibody
solution

13.

IX TBS

Non-fat, dry milk
protein - 2% (w/v)
IX TTBS - 98%
Antibody against protein
o f interest
Bovine serum albumin 5% (w/v)
IX TTBS - 95%
Antibody against protein
o f interest
Non-fat, dry milk
protein - 2% (w/v)
IX TTBS - 98%
Antibody against
primary antibody
10X TBS - 10% (v/v)
pH - 7.5

10 X running buffer 100 mL
Total V - 1 L
1OX running buffer 100 mL
Methanol - 200 mL
(add last)
Total V - 1 L
Tris - 24.2 g
N a C l - 116.9 g
Total V - 2 L
1OX T B S - 2 0 0 mL
Tween-20 - 2 mL
Total V - 2 L
a. Non-fat, dry milk
protein - 1.25 g
b. Bovine serum
albumin - 1.25 g
IX TTBS - top up to
25 mL
Non-fat, dry milk
protein - 0.4 g
IX TTBS - top up to
20 mL

4°C

4°C or
colder

Room
temperature
Room
temperature
Room
temperature

4°C (-20°C
long term)

Bovine serum albumin
- 1g
IX TTBS - top up to
20 mL

4°C (-20°C
long term)

Non-fat, dry milk
protein - 0.4 g
IX TTBS - top up to
20 mL

Room
temperature

lOXTBS-lOmL
Total V - 100 mL

Room
temperature
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Separating Gel Formulations'*
15 % Gel
2 gels

4 gels

6 gels

8 gels

ddH20

4.663 mL

9.325 mL

13.988 mL

18.65 mL

Acrylamide
solution1
Separating gel
buffer2
SDS solution3

10 mL

20 mL

30 mL

40 mL

5 mL

10 mL

15 mL

20 mL

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 pL

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

20 mL

40 mL

60 mL

80 mL

2 gels

4 gels

6 gels

8 gels

ddHzO

6.663 mL

13.325 mL

19.988 mL

26.65 mL

Acrylamide
solution1
Separating gel
buffer2
SDS solution3

8 mL

16 mL

24 mL

32 mL

5 mL

10 mL

15 mL

20 mL

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 pL

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

20 mL

40 mL

60 mL

80 mL

2 gels

4 gels

6 gels

8 gels

ddH20

7.996 mL

15.992 mL

23.988 mL

31.984 mL

Acrylamide
solution1
Separating gel
buffer2
SDS solution3

6.667 mL

13.333 mL

20 mL

26.667 mL

5 mL

10 mL

15 mL

20 mL

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 pL

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

20 mL

40 mL

60 mL

80 mL

12 % Gel

10 % Gel

Ill

7.5 % Gel
2 gels

4 gels

6 gels

8 gels

ddH20

9.663 mL

19.325 mL

28.988 mL

38.65 mL

Acrylamide
solution1
Separating gel
buffer2
SDS solution3

5 mL

10 mL

15 mL

20 mL

5 mL

10 mL

15 mL

20 mL

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 (J.L

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

20 mL

40 mL

60 mL

80 mL

2 gels

4 gels

6 gels

8 gels

ddH20

10.663 mL

21.325 mL

31.988 mL

42.65 mL

Acrylamide
solution1
Separating gel
buffer2
SDS solution3

4 mL

8 mL

12 mL

16 mL

5 mL

10 mL

15 mL

20 mL

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 pL

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

20 mL

40 mL

60 mL

80 mL

2 gels

4 gels

6 gels

8 gels

ddH20

5.992 mL

11.983 mL

17.975 mL

23.967 mL

Acrylamide
solution1
Stacking gel
buffer5
SDS solution3

1.333 mL

2.667 mL

4 mL

5.333 mL

2.5 mL

5 mL

7.5 mL

10 mL

100 pL

200 pL

300 pL

400 pL

10% APS solution

62.5 pL

125 pL

187.5 pL

250 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

10 mL

20 mL

30 mL

40 mL

6 % Gel

Stacking Gel Formulation6
4 % Gel
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Complete for ALL Staff Working Under This Protocol for This Renewal Year
TRAINING INFORMATION
CCAC Mandated Training Requirements - Ail personnel working with live animals require CCAC mandated training including the ‘Basic
Animal Care 3 Use Web-CT Course’and related hands-on 'Workshops \ Completion of the 'Basic Animal Care & Use Web-CT Course’ once
every 5 years is mandatory for ALL personnel, including the Principal Investigator. The Animal Use Subcommittee wilt be informed of all
personnel with incomplete training beyond f month of notice.
Workshop Enrolment Detail - The 1Workshop' requirements are determined by the species and procedures associated with each individual
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listed below. All personnel listed below will be contacted directly via the email address listed below for auto-enrolment in all ‘Workshop'
requirements. Previous hands-on ‘Workshops? attended at another research institution may be accepted; please submit training documentation
with this form. For additional training requirement detail and associated costs, go to
http://www.uwo.ca/animal/website/VS/Conteni/Teaching and Courses.htm __________

If ‘ YES' to HANDS-ON ANIMAL WORK.
CompleteThisSection PER SPECIES
_
PROCEDURES PE"R SPECIES

COMPLETE ALL COLUMNS BELOW PER PERSON

FIRST
NAME

LAST
NAME

Repeat
For
Each

Repeat
For
Each

Specie s

Species

Used

Used

ROLE

EMAIL
Address

(Role
within this
ProtocolÌ

Mandatory
Field*

Researcher
Staff
Student

Affiliated
institution
Emails
Preferred

UW Oê

HANDS
ON
Animal
Work?
YES

or
NO

SPECIES
One
Species
Per Row
Use an
Additional
Row for
Each
Species

1-Basic Handling
2-Health Monitoring
3=B!ocd Collection
^Injections
5=Anaesthesia
6-Surgery-Recovery
7—Su rgery-Non-Recovery
B^Euthanasia/Post Mortem
9-Other, Provide Detail Below, e.q. suti

Expected
START

DATE
nm idd/yy

2

3

4

5

6

7

a

9

0

0

s

0

0

0

0

0

0

1
Earl
Tomasz

Noble
Dztaloszyns
ki

l ì '0 1 / 0 9

Researcher enoble<s>uwo
S ta ff

ÌÌ0 H /U 9

0

El s

e

e

□

0

0

0

0

0

□

El

E

□

0

'0

u

0

a

□

0

a

□

0

0

0

Oscar

Campos

S tu d e n t

n 'o i '0 'í

0

0

Jordan

Silver

S tu d e n t

1 i / 0 1 -0 9

0

0

Mehrbod

Estaki

S tu d e n t

1 1 /0 1 --0 9

0

0

PROCEDURE #9 DETAIL
EMERGENCY AFTER HOURS
CONTACT NAMES & NUMBERS
- NO LAB PHONE NUMBERS If applicable, provide POST-OP
CARE personnel detail
If applicable, provide MONITORING
personnel detai

s

"M

0

r implantation of insulin pellets is necessary (EN and TD only); gavage for ginseng

IERGENCY CONTACT
.INITIAL : Noble E
IC O N D A R Y T m ERGENCY CONTACT
'LAST NAME & INITIAL : Dziaioszynski T

xi Same as Emergency Contact, or
l e : ____ _ _ _ _ _ _ _ _ _
lame as Emergency Contact, or
lam e:
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PRIMARY EMERGENCY CONTACT

NUMBER (HOME OR CELL): 519-472-8399
SECONDARY EMERGENCY CONTACT

NUMBER (HOME OR CELL) : 519-472-7371
E m e rg e n cy #: 519^72-8399 Lab #: 88373 E m ail:
enoble@uwo.ca

E m e rg e n cy #: 519-472-8399
enoble<o>uwo.ca

Lab #: 88373 E m ail:
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